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Abstract: Treated glioblastoma patients survive from 6 to 14 months. In the first part of this review, we describe glioma origins, cancer 
stem cells and the genomic alterations that generate dysregulated cell division, with enhanced proliferation and diverse response to radi-
ation and chemotherapy. We review the pathways that mediate tumour cell proliferation, neo-angiogenesis, tumor cell invasion, as well 
as necrotic and apoptotic cell death. Then, we examine the ability of gliomas to evade and suppress the host immune system, exhibited 
at the levels of antigen recognition and immune activation, limiting the effective signaling between glioma and host immune cells.
The second part of the review presents current therapies and their drawbacks. This is followed by a summary of the work of our labora-
tory during the past 20 years, on oligosaccharide and glycosphingolipid inhibitors of astroblast and astrocytoma division. Neurostatins, 
the O-acetylated forms of gangliosides GD1b and GT1b naturally present in mammalian brain, are cytostatic for normal astroblasts, but 
cytotoxic for rat C6 glioma cells and human astrocytoma grades III and IV, with ID50 values ranging from 200 to 450 nM. The inhibitors 
do not affect neurons or fibroblasts up to concentrations of 4 µM or higher.
At least four different neurostatin-activated, cell-mediated antitumoral processes, lead to tumor destruction: (i) inhibition of tumor neo-
vascularization; (ii) activation of microglia; (iii) activation of natural killer (NK) cells; (iv) activation of cytotoxic lymphocytes (CTL). 
The enhanced antigenicity of neurostatin-treated glioma cells, could be related to their increased expression of connexin 43. Because 
neurostatins and their analogues show specific activity and no toxicity for normal cells, a clinical trial would be the logical next step.
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Glioma Genomics
Central nervous system tumors
Gliomas belong to a group of diverse tumors that 
affect the brain and spinal cord, known as central 
nervous system neoplasms. A brain tumor is a mass 
of abnormal cells in the brain that have grown and 
multiplied in an uncontrolled fashion. Brain tumors 
developing from the various types of cells that make 
up the brain, are called primary brain tumors. Brain 
tumors are usually confined to the brain itself and 
only rarely spread to other parts of the body. Approxi-
mately 50% of all primary brain tumors originate from 
the specialized neural cells called glial cells and are 
called gliomas. Other types of glial cells, susceptible 
to develop primary brain tumors, include oligoden-
drocytes and ependymal cells. Primary brain tumors 
that develop from astrocytes are referred to as astro-
cytomas and they are the most common gliomas. In 
their fourth edition of the World Health Organization 
(WHO) classification of tumours of the central ner-
vous system, published in 2007, astrocytomas, were 
classified depending on their growth rate and their 
likelihood to spread (infiltrate) to nearby brain tissue, 
into the following four types or grades (Fig. 1):
•	 Grade I = Pilocytic Astrocytoma - This is a slow-
growing astrocytoma that usually does not spread 
to other parts of the central nervous system.
•	 Grade II = Low-Grade Astrocytoma - This is also 
a relatively slow-growing type of astrocytoma, but 
grows faster than pilocytic astrocytoma (Grade I). 
It may or may not invade the surrounding normal 
brain tissue and tends to recur after treatment.
•	 Grade III = Anaplastic Astrocytoma - This malig-
nant astrocytoma grows faster than grade II astro-
cytoma.  Invades  normal  brain  tissue  and  recurs 
after treatment.
•	 Grade  IV  =  Glioblastoma  Multiforme  (GBM). 
This  is  the  most  malignant  and  fastest  growing 
  astrocytoma.  Several  different  cell  types  can  be 
observed in the tumor under a microscope, includ-
ing astrocytes and oligodendrocytes. Areas of necro-
sis can also be observed at the center of the tumor. 
GBM invades very rapidly normal brain tissue.
About 22,000 people were diagnosed with a malig-
nant (cancerous) primary brain tumor in the United 
States  in  2010.  GBM,  the  most  common  type  of 
  primary malignant brain tumor in adults, accounted 
Figure 1. Chromosomal and genetic abnormalities involved in glioblastoma. The figure shows the relationships between survival, pathobiology, and the molec-
ular lesions that lead to the formation of primary (de novo) and secondary (progressive) glioblastomas. Grade Iv gliomas are histologically   indistinguishable, 
occur in different age groups and present distinct genetic alterations affecting similar pathways. Thus, inactivation of p53 function may be due to direct muta-
tion in progressive GBMs, or INK4aARF mutation/decrease in expression or MDM2 amplification in de novo GBMs. Similarly, activation of the PI3K pathway 
can be achieved by several cooperative mechanisms, including EGFR amplification and mutation, as well as PTEN mutation, although underexpression of 
PTeN in the absence of mutation is frequently seen as well.
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for 25% of all cases. GBM is most common in adults 
50 to 70 years of age and accounts for less than 10% 
of childhood brain tumors. It is more frequent in males 
than females, by an approximate ratio of 3:2.
Although malignant brain tumours make up only 
about 1.5 percent of all forms of cancer, GBM is almost 
always fatal. We are not much better at treating them 
than we were 5 or 10 years ago. GBM have small, 
microscopic  extensions  in  the  brain,  that  cannot  be 
removed surgically without sacrificing a large amount 
of normal brain tissue. Even then, unseen tumour cells 
are left behind. Therefore, the role of surgery is lim-
ited to: (1) obtaining biopsy tissue to characterize the 
tumour and (2) removing as much of the tumour as can 
be done safely, without causing   further neurological 
damage. Surgery alone cannot cure these tumours.
Researchers  have  learned  a  great  deal  about  the 
molecular and genetic events involved in the transfor-
mation of a “normal” cell to a “malignant” or cancer-
ous cell.1 Brain tumors, like other types of cancers, are 
caused by genetic mutations, some inherited and other 
acquired, ie, developing after exposure to risk factors, 
such as smoking or chemicals, that cause damage to 
the  genetic  material  of  the  cells.  Despite  extensive 
research to identify major risk factors, it appears that 
most primary brain tumors develop for no apparent rea-
son. Radiation therapy to the head for the treatment of 
other types of cancers, is currently the only established 
risk factor for developing a primary brain tumor. For 
example, children with leukemia, who receive radia-
tion therapy to the brain as part of their treatment, are 
at risk of developing a brain tumor later in life.
Most people who develop a primary brain tumor 
do  not  have  a  family  history  of  brain  tumors,  ie, 
inherited mutations do not appear to play a major role 
in the development of brain cancer. With the excep-
tion of exposure to ionizing radiation during radia-
tion therapy to the head for the treatment of other 
types  of  cancers,  there  is  no  clear-cut  association 
between exposure to other environmental risk fac-
tors and the development of brain tumors. It appears 
that most primary brain tumors develop for no appar-
ent reason, and the role in the development of pri-
mary brain tumors of environmental factors, genetic 
factors, and certain types of viruses, continues to be 
investigated.
Although the exact cause remains elusive, there is 
growing evidence that only a minor population of cells 
in  primary  brain  tumors  (GBM,  medulloblastoma, 
and ependymoma), are capable of forming a tumor when 
orthotopically   transplanted into immunocompromised 
mice.2
Cancer stem cells
There is no clear-cut association between exposure 
to environmental risk factors and the development of 
brain tumors. The link between exposure to certain 
chemicals (eg, vinyl chloride), petroleum products, 
and  chemicals  used  in  the  production  of  synthetic 
rubber, has been suspected but not proven, as a risk 
factor for brain tumors. More recently, the expansion 
of wireless cellular telephones has raised the concern 
about a possible link between radiofrequency expo-
sure from cellular phones and the development of 
brain tumors. Research in this area is ongoing, but 
an association between the use of cellular phones and 
brain tumors has not been found to date. Exposure 
to electromagnetic fields from high-tension wires has 
also been suspected as a risk factor for brain tumors. 
However, most studies have concluded that there is 
no strong evidence clearly proving an association.
With the exception of exposure to ionizing radiation 
during radiation therapy to the head for the treatment of 
other types of cancers, there is no clear-cut association 
between exposure to environmental risk factors and the 
development of brain tumors. Also, most primary brain 
tumors are developped by people who do not have a 
brain tumor family history, ie, inherited mutations do not 
appear to play a major role. It appears that most primary 
brain tumors develop for no obvious reason. Although 
the exact cause remains elusive, it appears that only a 
minor population of the cells in solid tumors, includ-
ing primary brain tumors (GBM, medulloblastoma, and 
ependymoma), are capable of forming a tumor when 
orthotopically  transplanted  into  an  immunocompro-
mised mouse.2 The concept of brain cancer stem cells 
(CSC)3 is based on the observation that only a small frac-
tion of primary leukemic cells are capable of initiating 
and sustaining clonogenic growth and inducing leuke-
mia in immunocompromised mice.4,5 Importantly, these 
leukemic subclones share cell surface markers (CD43+, 
CD38−) with “normal” hematopoietic stem cells (HSCs), 
while the progeny of these leukemic clones, the blast cells, 
often express more differentiated lymphoid or myeloid 
lineage markers and are not capable of producing leuke-
mic disease. At present it is unclear whether CSC derive Nieto-Sampedro et al
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from a normal stem cell compartment or from a more 
differentiated  progenitor,  that  dedifferentiates  into  a 
stem cell-like state. The identification of the “cell of ori-
gin” remains an area of active research for both hemato-
logical malignancies and solid tumors.2,6–14
The CSC hypothesis was independently proposed for 
GBM15 and pediatric gliomas.16 There were two critical 
findings in these studies. First, from a variety of pri-
mary CNS tumors (including GBM,   medulloblastoma, 
ganglioglioma,  ependymoma,  and  pilocytic  astrocy-
tomas), only a minor population of cells, identified in 
cell cultures, was able to self-renew and form clono-
genic neurospheres (Fig. 2). These self-renewing brain 
tumor cells were identified15 by the expression of the 
cell  surface  marker  CD133+ (prominin 1, PROM1, 
1%–35% of total population). In contrast, the CD133− 
population  failed  to  proliferate  and  remained  as  an 
adherent monolayer and expressed mature lineage spe-
cific markers. Second, CD133+ tumor neurospheres 
under  neural  stem  cell  (NSC)  culture  conditions, 
expressed the stem cell marker Nestin and, upon expo-
sure to serum, differentiated into a mixed population 
of neurons (Tuj1+), astrocytes (GFAP+), and oligo-
dendrocytes  (PDGFR+),  which  mirrored  the  mixed 
cell types found in the original patient’s tumor. These 
observations supported a hierarchical CSC hypothesis, 
suggesting that only CD133+ brain tumor cells can self-
renew and undergo lineage-specific differentiation.
Subsequently,  it  was  shown  that  FACS-sorted 
CD133+  cells  had  enhanced  tumor-forming  ability 
(as few as 100 implanted cells were able to produce 
orthotopic  tumors)  following  in  vitro  expansion.2 
Figure 2. Cancer Stem cells. CD133+ tumor cells show marked stem cell features. (A) CD133 immunohistochemistry shows plasma membrane staining in 
cells scattered within a medulloblastoma. Brain tumor stem cell from both medulloblastomas and pilocytic astrocytomas immunostained for CD133. (B) flow 
cytometry histogram in medulloblastoma tumor cells, the first peak representing cells negative for CD133 expression, and the second peak representing CD133 
positive cells. (c) CD133+ tumor cells proliferated in culture as nonadherent spheres, whereas CD133− tumor cells adhered to culture dishes, did not proliferate 
and did not form spheres.
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In contrast, CD133− cells failed to form tumors, even 
following injection of a much larger cell innoculum. 
The orthotopic tumors mirrored the original tumor het-
erogeneity, with CD133+ cells forming a minor fraction 
and the CD133− cells failing to form tumors on serial 
transplantation. These data suggest that loss of CD133 
expression  reflects  an    “irreversible”  loss  of  cellular 
ability to propagate a tumor. Whether CD133+ cells are 
only important for tumor initiation and are less critical 
for tumor progression, will require a genetic strategy 
similar to that used to monitor skin stem cells in vivo, 
using a doxycyline-inducible H2B-eGFP reporter tag, 
to permit selection of CD133+ cells over time.17
Cancer-forming  ability  in  vivo  is  very  much 
increased in CD133+ cells for GBM2,18,19 and colon 
cancer.10,20 There  are,  however,  a  number  of  reports 
suggesting  a  less  clear  distinction  between  the  abil-
ity of CD133+ and CD133− cells to form orthotopic 
tumors.21–24 Thus, Beier et al23 reported that CD133− 
cells  isolated  from  primary  GBM  tumors  were  as 
capable of forming orthotopic tumors as CD133+ cells, 
whereas under the same conditions none of the second-
ary GBM tumors (zero of seven) produced viable neu-
rosphere cultures.23 The same authors also reported that 
in 4 of 11 primary GBM tumors, CD133− cells grew as 
an adherent monolayer, yet were able to produce ortho-
topic tumors. Similarly, CD133− primary GBM tumor 
cells, maintained as an adherent monolayer by addition 
of serum to stem cell culture media, were also able to 
produce highly infiltrative orthotopic tumors.22 These 
data indicate that even brief ex vivo manipulations may 
alter the molecular and phenotypic properties of freshly 
  isolated tumor cells and complicate the conclusions that 
can be drawn from this type of experiments, pointing to 
the need for studies using directly isolated tumor cells 
from fresh specimens and immediate implantation into 
immunocompromised mice. While the GBM-stem cell 
idea is in its infancy and many questions remain, its 
potential for our understanding of tumor development 
and  therapy  design  and   selection  is  exciting  indeed. 
Tumour relapse often occurs after conventional therapy, 
whereas therapy specific for cancer stem cells will lead 
to complete tumour regression (Fig. 3).
Genomic alterations in clinical  
GBM subtypes
The  Cancer  Genome  Atlas  (TCGA)  Research 
  Network was established to generate the catalogue 
of  genomic  abnormalities  driving  tumorigenesis. 
TCGA  provided  a  detailed  view  of  the  genomic 
changes  in  a  large  GBM  cohort  containing  206 
patient samples.24 Sequence data of 91 patients and 
601  genes  were  used  to  describe  the  mutational 
spectrum of GBM (Fig. 1), confirming previously 
reported  TP53  and  RB1  mutations  and  identify-
ing  GBM-associated  mutations  in  such  genes  as 
PIK3R1, NF1, and ERBB2. Projecting copy number 
and mutation data on the TP53, RB, and receptor 
tyrosine kinase pathways, showed that the majority 
of GBM tumors harbor abnormalities in all of these 
pathways, suggesting that this is a core requirement 
for GBM   pathogenesis. Human cancer cells typically 
harbour multiple chromosomal aberrations, nucle-
otide  substitutions  and  epigenetic  modifications 
that drive malignant transformation. This   analysis 
  provides  new  insights  into  the  roles  of  ERBB2, 
NF1 and TP53, uncovers frequent   mutations of the 
phosphatidylinositol-3-OH  kinase  regulatory  sub-
unit gene PIK3R1, and provides a network view of 
the pathways altered in the development of glioblas-
toma. Furthermore, integration of mutation, DNA 
methylation and clinical treatment data reveals a link 
between DNA methyltransferase promoter methyla-
tion and a hypermutator phenotype consequent to 
mismatch repair deficiency in treated glioblastomas, 
an observation with potential clinical implications.
Thirty  heterozygous  deletions  in  NF1  were 
observed among the sample set of 206 cases, 6 of 
which also harbour point mutation.24 Some samples 
also exhibited loss of expression without evidence 
of genomic alteration. Overall, at least 47 of the 206 
patient samples (23%) harboured somatic NF1 inac-
tivating mutations or deletions, definitively address-
ing NF1’s relevance to sporadic human glioblastoma. 
It was concluded that NF1 is a human glioblastoma 
suppressor gene.
EGFR is frequently activated in primary glioblasto-
mas. Variant III deletion of the extracellular domain (‘vIII 
mutant’) has been the most commonly described event, 
in addition to extracellular domain point mutations and 
cytoplasmic  domain  deletions.24  Here,  high-resolution 
genomic and exon-specific transcriptomic profiling read-
ily detected vIII and carboxy-terminal deletions with 
correspondingly altered transcripts. Among the 91 glio-
blastoma cases with somatic mutation data, 22 harboured 
focal  amplification  of  wild-type  EGFR  with  nopoint Nieto-Sampedro et al
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mutation, 16 had point mutations in addition to focal 
amplification, and 3 had EGFR point mutations but 
no amplification. Collectively, EGFR alterations were 
observed in 41 of the 91 sequenced samples.24
ERBB2 mutation has previously been reported in 
only one glioblastoma tumour.24 In the TCGA cohort, 
11  somatic  ERBB2  mutations  in  7  of  91  samples 
were validated, including 3 in the kinase domain and 
2 involving V777A, a site of recurrent missense and 
in-frame insertion mutations in lung, gastric and colon 
cancers.  The  remaining  eight  mutations  (including 
seven missense and one splice-site mutation) occurred 
in the extracellular domain of the protein, similar to 
somatic EGFR substitutions in glioblastoma. Unlike 
in breast cancers, focal amplifications of ERBB2 were 
not observed in glioblastomas.
Various somatic mutations of the PI(3)K complex 
are relevant in human glioblastoma. PI3Ks catalyze 
the  mitogen-stimulated  phosphorylation  of  phos-
phatidylinositol-4,5  bisphosphate  [PtdIns(4,5)P2]  to 
produce  PtdIns(3,4,5)P3.  The  PI(3)K  complex  con-
sists of a catalytically active protein, p110a, encoded 
by PIK3CA, and a regulatory protein, p85a, encoded 
by PIK3R1. Frequent activating missense mutations of 
PIK3CA have been reported in multiple tumour types, 
including glioblastoma.25,26 These mutations occur pri-
marily in the adaptor binding domain (ABD) as well 
as the C2 helical and kinase domains. Indeed, PIK3CA 
somatic nucleotide substitutions were detected in 6 of 
the 91 sequenced samples.24 Apart from the four muta-
tions already reported in the COSMIC database,27 two 
novel in-frame deletions were detected in the adaptor 
binding domain of PIK3CA (‘L10 del’ and ‘P17 del’). 
Those  deletions  may  disrupt  interactions  between 
p110a and its regulatory subunit, p85a.28
Somatic mutations in the genes  
IDH1 and IDH2
Sequencing of matched tumor and normal gene sam-
ples led to the unexpected finding of somatic point 
mutations in the genes for two isocitrate dehydroge-
nase isoenzymes, IDH1 and IDH2. The IDH enzymes 
play a key role in cellular metabolism, catalyzing the 
conversion of isocitrate to α-ketoglutarate and gen-
erating NADPH from NADP in the process. Mutated 
IDH1 was found in 12% of glioblastoma multiforme 
Cancer stem cell
specific therapy
Conventional
cancer therapy
Tumor regression
Tumor relapse
Figure 3. Conventional vs. specific glioma therapies. Cancer stem cells (CSCs) may generate tumors through processes of self-renewal and   differentiation. 
CSCs may persist in tumors as a distinct population and cause relapse and metastasis, giving rise to new tumors. Because CSCs form a very small propor-
tion of the tumor, conventional chemotherapies may not necessarily act specifically on the stem cells, killing differentiated or differentiating cells, that form 
the bulk of the tumor, whereas CSCs may remain untouched and cause a relapse.Glioma growth inhibition
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samples  analyzed29  and  mutations  at  arginine  132 
(R132) of IDH1 were found in more than 80% of 
secondary GBMs. These mutations strongly reduced 
the  ability  of  the  enzyme  to  convert  isocitrate  to 
α-ketoglutarate, compared with the wild-type enzyme 
and further kinetic analyses revealed a dramatically 
reduced affinity for isocitrate in the mutants. On exam-
ining gliomas negative for IDH1 mutations, recurrent 
somatic mutations of IDH2 at the analogous R172 
residue were identified.30,31 Not only were the IDH1 
and IDH2 mutations frequent, but studies by several 
laboratories  established  that  the  mutation  in  IDH1 
occurred early in glioma progression.32 Notably, the 
mutations affected only one allele of the IDH locus 
(of the two alleles of either IDH1 or IDH2, but not 
both in the same tumor), which is puzzling consider-
ing that they are selected for early in tumorigenesis.
The  IDH  enzymes  play  a  key  role  in  cellular 
metabolism. The crystal structure of IDH134 predicts 
that the amino acid substitutions at the R132 posi-
tion will impair the interaction of the enzyme with 
its isocitrate substrate, Zhao and colleagues34 evalu-
ated the in vitro enzymatic activities of three tumor-
derived IDH1 mutants and observed that they had a 
more than 80% reduced ability to convert isocitrate to 
α-ketoglutarate, compared with the wild-type enzyme. 
Kinetic  analyses  revealed  a  dramatically  reduced 
affinity for isocitrate in the three mutants. As IDH1 
functions as a homodimeric complex, Zhao et al34 iso-
lated IDH1 dimers expressed from the R132H mutant 
and wild-type genes introduced into Escherichia coli. 
Three dimer combinations were identified, the wild-
type:R 132H heterodimer exhibited only 4% of the 
wild-type dimer enzyme activity, while R132H:R132H 
homodimers were almost completely inactive.
What are the metabolic consequences of IDH1 muta-
tions? Using the U-87MG human glioblastoma cell 
line, Zhao et al34 demonstrated a concomitant reduc-
tion in cellular α-ketoglutarate levels after knocking 
down endogenous IDH1. Because α-ketoglutarate is 
required by prolylhydroxylases, enzymes that hydroxy-
late and promote the degradation of hypoxia-inducible 
factor 1α (HIF-1α), the intracellular levels of HIF-1α 
were  also  reduced.  Zhao  et  al34  showed  that  when 
wild-type IDH1 was knocked down by RNA interfer-
ence, HIF-1α was elevated, and when IDH1 was over-
expressed, HIF-1α levels were reduced. HIF-1α is a 
component of HIF-1, a transcription factor that regu-
lates the expression of genes related to glucose metab-
olism, angiogenesis, and other signaling pathways, by 
sensing low cellular oxygen levels. Using quantitative 
PCR to measure the transcripts of three known HIF-1 
target  genes—glucose  transporter  1  (Glut1),  vascu-
lar endothelial growth factor (VEGF), and phospho-
glycerate kinase (PGK1)—Zhao et al34 demonstrated 
induced expression of these genes as a consequence of 
either the knockdown of wild-type IDH1 or the expres-
sion of the IDH1 R132H mutant. On staining glioma 
samples for HIF-1α, the tumors with previously iden-
tified R132H mutations showed a statistically stronger 
staining signal than those without mutations. Thus, the 
function of mutated IDH1 was reduced and the down-
stream impact of that reduced function (the consequen-
tial upregulation of HIF-1α) contributed to the cell’s 
progression to cancer, indicating that a likely function 
of IDH1 is that of a tumor suppressor gene and that 
IDH2 may have a similar role.35
Building  on  the  initial  characterizations  of 
IDH1 mutations in gliomas, Dang et al36 took a metab-
olomics-based approach to identify additional changes 
in  metabolite  levels  when  an  IDH1  mutation  was 
  present.36 They found 2-hydroxyglutarate to be the only 
metabolite with significantly increased abundance in 
cells expressing the R132H mutant IDH1. The increase 
in  2-hydroxyglutarate  resulted  from  the  NADPH-
  dependent  reduction  of  α-ketoglutarate  by  mutant 
IDH1, a new function enabled by the mutation at R132. 
The authors demonstrated a similar gain of function for 
the R132C, R132L and R132S   mutations. Their X-ray 
crystallographic studies showed that the R132H muta-
tion in IDH1 results in the formation of an active site 
distinct from that of the wild-type enzyme. With the aim 
of improving diagnostic efficacy, Dang et al36 examined 
12 GBM tumors with various R132 mutations in IDH1, 
and found 2-hydroxyglutarate levels 100-fold greater 
or more than in tumors with wild-type IDH1; the mea-
sured decrease in α-ketoglutarate was, however, not 
statistically different in mutant versus wild-type IDH1 
tumors. This finding indicates that in the clinic, detect-
ing patients with increased 2-hydroxyglutarate levels 
would identify GBMs with IDH1 mutations, predicting 
an overall longer survival time. Indeed, since secondary 
GBMs develop from lower-grade gliomas, therapeutic 
inhibition of 2-hydroxyglutarate production might slow 
the transition time to GBM development, offering an 
improved survival benefit as a result.Nieto-Sampedro et al
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Mardy’s laboratory used a whole-genome shotgun 
approach  to  sequence  tumor  genomes.  In  the  sec-
ond case of acute myeloid leukemia sequenced, they 
discovered an IDH1 R132 mutation that was subse-
quently found in about 8% of our 187 banked acute 
myeloid leukemia patient samples, showing that this 
mutation  was  not  restricted  to  gliomas.37 A  subse-
quent study by Gross et al38 examined an additional 
145 acute myeloid leukemia biopsies, identifying 11 
IDH1 R132 mutant samples.38 Four IDH1-mutant pri-
mary samples had relapse samples that also carried the 
IDH1 mutation. Acute myeloid leukemia cells carrying 
the R132 mutant of IDH1 were found by gas chroma-
tography-mass  spectrometry  to  have  2-hydroxyglu-
tarate levels around 50-fold greater than in samples 
with  wild-type  IDH1.  Similarly,  higher  2-hydroxy-
glutarate levels were detected in sera from patients 
positive for the IDH1 R132 mutation. Two wild-type 
IDH1  samples  had  elevated  2-HG  levels  and  were 
found to be carrying IDH2 R172 mutations, the first 
report of these in acute myeloid leukemia. Because of 
the apparent predominance in acute myeloid leukemia 
of the IDH1 R132C mutation over R132H (which is 
more predominant in gliomas), Gross et al38 looked at 
the kinetics of the R132C mutant enzyme. The R132C 
enzyme showed a dramatic loss of affinity for isoci-
trate (resulting in a reduction in KM) and a drop of 
more than six orders of magnitude in net efficiency 
(Kcat/KM) of isocitrate metabolism.
Another  recent  study  has  extended  our  under-
standing of IDH mutations and their detection. Ward 
et al39 have shown that the gain of function seen in 
the IDH1 R132 mutants (that is, the ability to reduce 
α-ketoglutarate)  is  also  found  in  the  IDH2  R172K 
mutant. Metabolic profiling of cells expressing IDH2 
R172K revealed an approximately 100-fold increase in 
intracellular 2-hydroxyglutarate compared with cells 
overexpressing wild-type IDH2, and this finding was 
extended to leukemia cells carrying the IDH2 R172K 
mutation. Ward et al39 also screened acute myeloid leu-
kemia samples with normal cytogenetics but unknown 
IDH mutational status for increased levels of 2-hydrox-
yglutarate,  and  then  evaluated  the  mutational  status 
based on the result of the screening assay. In this test, 
2-hydroxyglutarate measurement was found to predict 
mutational status with high accuracy.39
This  work,  aiming  to  characterize  the  impact  of 
IDH mutations on tumor cell biology, has led to the 
conclusion that all mutations discovered so far, enable 
a gain of function in α-ketoglutarate reduction with a 
concomitant increase in the tumor-specific metabolite, 
or oncometabolite, 2-HG. Although the contribution 
of 2-hydroxyglutarate to tumor cell biology remains 
speculative, Ward et al39 noted that all IDH mutation-
containing tumor types identified so far (leukemias and 
gliomas) are distinguished by proliferation of a rela-
tively undifferentiated cell population. In this context, 
the effect of 2-hydroxyglutarate on the tumor and its 
microenvironment is to block cellular differentiation.39
DNA methyltransferase methylation and 
mismatch repair in treated glioblastomas
Tumour cell-derived gelatinases (matrix metallopro-
teinase-2, matrix metalloproteinase-9, MGMT) can be 
considered prime factors in glioma   invasiveness: their 
expression  correlates  with  the  progression  and  the 
degree of malignancy.40 Alkylating agents are the most 
widely used chemotherapeutic agents to treat GBM. 
Among the chemotherapeutic compounds used in its 
treatment, temozolomide (TMZ), a cytotoxic alkylating 
agent, has shown activity in recurrent glioblastoma.41–44 
Epigenetic  silencing  of  O6-  methylguanine-DNA-
methyltransferase (MGMT) gene by promotor methy-
lation was among the strongest predictors of survival 
in the European-Canadian study for newly diagnosed 
GBM.45 Patients with tumors harboring MGMT pro-
moter  methylation  clearly  benefit  most  from  com-
bined RT/TMZ. Cancer-specific DNA methylation of 
CpG dinucleotides located in CpG islands within the 
promoters of 2,305 genes, was measured relative to 
normal brain DNA.24 The promoter methylation sta-
tus of MGMT, a DNA repair enzyme that removes 
alkyl  groups  from  guanine  residues,46  is  associated 
with glioblastoma sensitivity to alkylating agents.47,48 
Among the 91 sequenced cases, 19 samples were found 
to  contain  MGMT  promoter  methylation  (including 
13 of the 72 untreated cases and 6 of the 19 treated 
cases; see below, chemotherapy).24 When juxtaposed 
with  somatic  mutation  data,  an  intriguing  relation-
ship between the hypermutator phenotype and MGMT 
methylation  status  emerged  in  the  treated  samples. 
Specifically, MGMT methylation was associated with 
a profound shift in the nucleotide substitution spectrum 
of treated glioblastomas. Among the 13 treated sam-
ples without MGMT methylation, 29% (29 out of 99) 
of the validated somatic mutations occurred as GNC to Glioma growth inhibition
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ANT transitions in CpG dinucleotides (characteristic 
of spontaneous deamination of methylated cytosines), 
and a comparable 23% (23 out of 99) of all mutations 
occurred as GNC to ANT transitions in non-CpG dinu-
cleotides. In contrast, in the six treated samples with 
MGMT methylation, 81% of all mutations (146 out of 
181) turned out to be of the GNC to ANT transition 
type in non-CpG dinucleotides, whereas only 4% (8 out 
of 181) of all mutations were GNC to ANT transition 
mutations within CpGs. That pattern is consistent with 
a failure to repair   alkylated guanine residues caused 
by  treatment.  In  other  words,  MGMT  methylation 
shifted the mutation spectrum of treated samples to a 
preponderance of GNC to ANT transition at non-CpG 
sites. Notably, the mutational spectra in the mismatch 
repair  (MMR)  genes  themselves  reflected  MGMT 
methylation  status  and  treatment  consequences. All 
seven mutations in MMR genes found in six MGMT 
methylated,   hypermutated (treated) tumours occurred 
as GNC to ANT mutations at non-CpG sites, whereas 
neither MMR mutation in non-methylated, hypermu-
tated tumours was of this characteristic. Hence, MMR 
deficiency  and  MGMT  methylation  together,  in  the 
context  of  treatment,  exerted  a  powerful  influence 
on the overall frequency and pattern of somatic point 
mutations in glioblastoma tumours, an observation of 
potential clinical importance. In some Phase II clini-
cal trials, the combined therapy with marimastat (MT), 
a broad spectrum matrix metalloproteinase inhibitor, 
plus other chemotherapeutic agents, compared to con-
ventional therapy for glioma, has provided promising 
antitumor  effects,  although  musculoskeletal  toxicity 
was observed.49,50
Mitogenic pathways in Glioma
Cell cycle dysregulation and enhanced 
glioma cell proliferation
Cell cycle regulatory genes have a great importance 
for glioma growth, as underscored by the frequent 
mutations of these genes in cellular proliferation and 
senescence.  The  RB  and  p53  pathways,  that  gov-
ern  the  G1-to-S-phase  transition  in  the  cell  cycle, 
suffer inactivating mutations in GBM (Fig. 4). The 
absence or misfunction of these guardians of the cell 
cycle, renders tumoral cells susceptible to cell divi-
sion driven by constitutively active mitogens, such as 
phosphoinositide 3-kinase (PI3K) and mitogen-acti-
vated protein kinase (MAPK).
The Rb pathway
In  quiescent  cells,  hypophosphorylated  RB  blocks 
proliferation  by  binding  and  sequestering  the  E2F 
family  of  transcription  factors,  which  prevent  the 
transactivation  of  genes  essential  for  progression 
through  the  cell  cycle.51  Upon  mitogenic  stimula-
tion, the activation of the MAPK cascade leads to the 
induction of cyclin D1 and its association with the 
cyclin-dependent kinases CDK4 and CDK6, as well 
as the degradation of the CDK2/cyclin E inhibitor, 
p27  Kip1.52–54  These  activated  CDK  complexes  in 
turn phosphorylate RB, enabling E2F transactivation 
of its direct transcriptional targets governing S-phase 
entry and progression55,56 (Fig. 4).
Gliomas circumvent RB-mediated cell cycle inhibi-
tion through any of several genetic alterations. The Rb1 
gene, which maps to chromosome 13q14, is mutated in 
nearly 25% of high-grade astrocytomas and the loss 
of 13q typifies the transition from low- to intermedi-
ate-grade gliomas.57,58 Moreover, amplification of the 
CDK4 gene on chromosome 12q13–14 accounts for 
the functional inactivation of RB in 15% high-grade 
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Figure 4. Cell division checkpoints. The cell cycle proceeds by a defined 
sequence of events that ensures that complete and accurate replicas 
of the genome reach daughter cells. To monitor this process, cells are 
equipped with checkpoints at various stages of the cycle. DNA damage 
activates at least 3 checkpoints, that arrests cell cycle: in G1/S (G1) check-
point, intra-S phase checkpoint, and G2/M checkpoint. Perturbation of 
DNA replication by drugs that interfere with DNA synthesis, DNA lesions, 
or obstacles on DNA, activate the DNA replication checkpoint, that arrests 
cell cycle at G2/M transition, until DNA replication is complete. Additional 
checkpoints, such as the morphogenesis checkpoint, detect abnormality 
in cytoskeleton and arrests the cell cycle at the G2/M transition.Nieto-Sampedro et al
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gliomas, and CDK6 is also amplified but at a lower 
frequency.59,60 RB activity is also frequently lost through 
the inactivation of a critical negative regulator of both 
CDK4 and CDK6, p16Ink4a.61 This gene is one of two 
transcripts generated at the CDKN2A locus on chro-
mosome 9p21 (in addition to p14 ARF, p14 alternate 
reading frame), which is   predominantly inactivated by 
allelic loss or hypermethylation in 50%–70% of high-
grade gliomas and about 90% of cultured glioma cell 
lines.62–66   Consistent with its role as an important glioma 
tumor suppressor, p16Ink4a is also a critical inhibitor 
of progenitor cell renewal in the subventricular zone 
of aging mice.67 The importance of the inactivation of 
the RB pathway in glioma progression is evidenced 
by the near-universal, and mutually exclusive, altera-
tion of RB pathway effectors and inhibitors, in both 
primary and secondary GBM.68,69 However, numerous 
in vitro and in vivo assays have demonstrated that the 
neutralization of this pathway alone is insufficient to 
abrogate cell cycle control, to the extent needed for 
cellular transformation. Therefore, other important cell 
cycle regulation pathways probably complement their 
activities in preventing gliomagenesis.70–78
The p53 pathway
The p53 tumor suppressor prevents the propagation of 
cells with unstable genomes, predominantly by halting 
the cell cycle in the G1 phase or instigating a program 
of apoptosis or proliferative arrest.79 P53 achieves these 
ends primarily through its function as a transcription 
factor:  upon  being  post-translationally  modified  by 
various genotoxic and cytotoxic stress-sensing agents, 
p53 is stabilized, then binds and transcriptionally regu-
lates the promoters of more than 2500 potential effec-
tor genes.80,81 The best characterized of these effectors 
is the transcriptional target CDNK1A, that encodes the 
protein for the CDK2 inhibitor p21.82,83 Although this 
gene has not been found to be genomically altered in 
gliomas, its expression is frequently abrogated by p53 
functional inactivity, as well as by mitogenic signaling 
through the PI3K and MAPK pathways.
The  p53  pathway  is  almost  invariably  altered  in 
sporadic  gliomas.  Loss  of  p53,  through  either  point 
mutations that prevent DNA binding or loss of chro-
mosome  17p,  is  a  frequent  and  early  event  in  the 
pathological progression of secondary GBM.84,85 The 
importance of p53 in gliomagenesis is also underscored 
by the increased incidence of gliomas in Li-Fraumeni 
  syndrome, a   familial cancer-predisposition associated 
with germline p53 mutations.86,87 This genetic linkage 
has been reinforced by a glioma-prone condition in mice 
engineered with a p53   mutation commonly observed in 
Li-Fraumeni,88 as well as in p19 ARF-null mice.89
The finding that a second promoter drives an alterna-
tively spliced transcript at the CDKN2A locus prompted 
the discovery of an additional tumor suppressor gene 
that is inactivated at this locus.90 The second protein 
encoded  by  CDKN2A,  p14 ARF,  was  subsequently 
shown to be an important accessory to p53 activation, 
under conditions of oncogenic stress due to neutraliza-
tion of the p53 ubiquitin ligase, MDM2.91–94 This onco-
gene was originally found amplified in a spontaneously 
transformed murine cell line, and later discovered to be 
a key negative regulator of p53 during normal devel-
opment and in tumorigenesis.95–102 Concordantly, the 
chromosomal  region  containing  MDM2,  12q14-15, 
was  amplified  in  about  10%  of  primary  GBM,  the 
majority of which contained intact p53.59 The discov-
ery of the MDM2-related gene, MDM4 (chromosome 
1q32), which inhibits p53 transcription and enhances 
the ubiquitin ligase activity of MDM2, prompted the 
finding that the p53 pathway is also inactivated by 
the amplification of MDM4 in 4% of GBM with nei-
ther  TP53  mutation  nor  MDM2  amplification.103–106 
  Additionally, the tumor suppressor gene CHD5 (chro-
modomain helicase DNA-binding domain 5), which 
maps to chromosome 1p36 and is therefore, frequently 
hemizygously  deleted  in  those  human  gliomas  that 
have 1p loss, has been shown to maintain p53 levels 
by facilitating expression of p19 Arf (mouse p14 Arf 
ortholog), and thus presents an additional mechanism 
for inactivation of this critical pathway.68
Mitogenic signaling pathways
Many mitogens and their specific membrane receptors 
are present in overactive form in gliomas. Proliferation 
of normal cells requires activation of mitogenic signal-
ing pathways through diffusible growth factor binding, 
cell–cell  adhesion,  and/or  contact  with  extracellular 
matrix  (ECM)  components. These  signals  are  trans-
duced intracellularly by transmembrane receptors that 
typically activate the PI3K and MAPK signaling path-
ways. In contrast, tumor cells acquire genomic altera-
tions that greatly reduce their dependence on exogenous 
growth  stimulation,  enabling  their  inappropriate  cell 
division, survival, and motility through the constitutive Glioma growth inhibition
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activation of these pathways. While gliomas overcome 
the  normal  impositions  on  the  control  of  mitogenic 
signaling through multiple mechanisms, activation of 
receptor tyrosine kinases (RTKs), discussed in detail 
below, appears to be the predominant mechanism.
MAPK
The MAPK pathway can transduce proliferation sig-
nals by both integrins and receptor tyrosine kinases 
(RTKs). Integrins are membrane-bound extracellular 
matrix (ECM) receptors, that mediate the interaction 
between the ECM and the cytoskeleton. Upon   adhesion 
to ECM, integrins bind cytoplasmic anchor proteins 
that coordinate the binding of integrins to actin fila-
ments, thus creating a focal adhesion complex.
Multiple molecules of focal adhesion kinase (FAK) 
cluster at these complexes and become activated by 
crossphosphorylation,  whereupon  FAK  activates  a 
signal transduction cascade that leads to extracellular 
signal regulated kinase (ERK) phosphorylation. This 
takes place either through activation of Ras, recruiting 
the adaptor protein Grb2 and the Ras guanine nucleotide 
exchange factor SOS to phospho-FAK at the plasma 
membrane, or through Src-dependent phosphorylation 
of  p130Cas.107–109  Ras-GTP,  in  turn,  phosphorylates 
Raf kinase, which phosphorylates MEK, which phos-
phorylates  ERK.  The  phosphorylated  kinase  enters 
the nucleus and phosphorylates nuclear transcription 
factors, that induce the expression of genes promot-
ing cell cycle progression, such as cyclin D1 (Fig. 4). 
RTKs  activate  the  MAPK  pathway  when  activated 
by growth factor signaling, mutation, or overexpres-
sion. RTK activation results in receptor dimerization 
and cross-phosphorylation, creating binding sites for 
adaptor protein complexes such as Grb2/SOS, which 
in turn activates Ras. Whereas mutated forms of Ras, 
constitutively activated, are found in about 50% of all 
human tumors, few Ras mutations have been found 
in gliomas. However, high levels of active Ras-GTP 
are  found  in  advanced  astrocytomas,110  suggesting 
that a more relevant mechanism for MAPK-dependent 
mitogenic signaling in GBM is through inappropriate 
activation of RTKs and/or integrins.
PI3K/PTeN/AKT
Class  I  kinases  (PI3Ks)  catalyze  the  mitogen-
  stimulated  phosphorylation  of  phosphatidylinositol- 
4,5-bisphosphate  [PtdIns(4,5)P2]  to  produce  Ptd 
Ins(3,4,5)P3. This creates docking sites for a   multitude 
of    signaling  proteins  containing  domains  capa-
ble  of  binding  either  PtdIns(3,4,5)P3  itself  or  the 
5-  dephosphorylated product, PtdIns(3,4)P2.111,112 Class 
IA PI3Ks are heterodimers, recruited to activated RTKs 
and adaptor proteins via their regulatory subunit, of 
which there are five isoforms encoded by three genes: 
p85 (PIKR2), p55 (PIKR3), and p50 (PIK3R1).
Because the regulatory subunits appear function-
ally equivalent, class IA PI3Ks are currently defined 
by  their  catalytic  isoforms  p110,  encoded  by  the 
PIK3CA, PIK3CB, and PIK3CD genes,   respectively.112 
Evidence for the importance of p110 in transforma-
tion, derives from the discovery of a vPIK3CA onco-
gene in avian sarcoma virus with potent transforming 
activity  in  chicken  embryo  fibroblasts.113  PIK3CA 
gain-of-function  point  mutants  have  been  detected 
in a variety of cancers, including malignant gliomas 
such as GBM, in which the frequency of mutation has 
been cited in some studies to be as high as 15%.25,26 
Elevated expression of the PIK3D gene has also been 
reported in GBM.114,115
The p110 subunits can be activated by binding both 
p85 and GTP-bound Ras.116,117 Recently, the study of 
mice bearing a p110 point mutant unable to bind Ras, 
revealed that this interaction is essential both, for nor-
mal development and for Ras-driven tumorigenesis, 
as assessed both by transformation of mouse embry-
onic fibroblasts by H-Ras and by using a mouse model 
of K-ras-induced lung adenocarcinomas.118
The  action  of  class  I  PI3K  enzymes  is  directly 
antagonized by the PtdIns(3,4,5) P3 3-phosphatase 
encoded by the PTEN gene, located at 10q23.3.119–121 
PTEN is a major tumor suppressor that is inactivated 
in 50% of highgrade gliomas by mutations or epi-
genetic mechanisms, each resulting in uncontrolled 
PI3K signaling in these tumors.114,122 In mouse mod-
els, brain-specific inactivation of PTEN caused over-
growth of the mouse brain and aberrant proliferation 
of astrocytes, both in vivo and in vitro.123 An elegant 
mouse model of astrocytoma has been developed in 
which the Rb family of proteins are inactivated by 
GFAP-directed expression of SV40 T antigen.78 In 
this  model  system,  PTEN  inactivation  was  associ-
ated  with  increased  angiogenesis—a  close  parallel 
to the progression of high-grade glioma in humans, 
coincident with loss of PTEN.78,124 While regulation 
of  PI3K  signaling  is  critical  for  controlling  cell Nieto-Sampedro et al
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growth and survival, a number of recent studies have 
pointed to additional levels at which PTEN may act 
to  suppress  transformation  and  tumor  progression. 
Differentiated and quiescent cells harbor high lev-
els of nuclear PTEN, which appears to fulfill impor-
tant roles in the maintenance of genomic integrity, 
through  centromere  stabilization  and  promotion  of 
DNA repair.124 Importantly, a number of PTEN point 
mutations  found  in  familial  cancer  predisposition 
syndromes  have  no  effect  on  enzyme  activity,  but 
instead lie within sequences important for regulating 
PTEN localization. Analysis of such mutants has con-
firmed that aberrant sequestration of PTEN into either 
the nucleus or the cytoplasm compromises its tumor 
suppressor function.125,126
The  phosphoinositide-dependent  kinase  (PDK1) 
and Akt/PKB (the cellular homolog of a viral onco-
protein),  are  two  of  the  many  signaling  proteins 
recruited  to  the  membrane  and  activated  by  bind-
ing to PtdIns(3,4,5)P3, required for tumorigenesis in 
PTEN+/− mice and for growth of PTEN−/− embryonic 
stem (ES) cells as tumors in nude mice. In response 
to PI3K activation, PDK1 and the mammalian target 
of rapamycin mTOR, acting in the rapamycin-insen-
sitive TORC2  complex,  activate Akt  via  phospho-
rylation of two key residues, T308 and S473.127,128 
Assessment  of  the  phosphorylation  status  of  these 
residues is often the method of choice for monitor-
ing PI3K pathway activity in cell lines and primary 
tumors, including GBM samples, 85% of which have 
been  reported  to  display  activated Akt.129  In  addi-
tion to aberrant PI3K signaling, there are a number 
of other possible mechanisms by which Akt activa-
tion may become dysregulated in GBM. PHLPP (PH 
domain  leucine-rich  repeat  protein  phosphatase), 
which dephosphorylates S473, is expressed at very 
low levels in certain GBM cell lines, as is CTMP 
(C terminal modulator protein), which binds to Akt 
and  inhibits  its  phosphorylation.130–132  PIKE-A,  a 
small GTPase highly expressed in GBMs and glioma 
cell lines, binds directly to phosphorylated Akt and 
enhances its anti-apoptotic function.133,134
Akt phosphorylates many proteins involved in the 
regulation of cell growth, proliferation, metabolism, 
and apoptosis. A recent study on v-H-ras-induced trans-
formation of MEFs and skin carcinogenesis, indicates 
that activation of mTOR in the rapamycin-sensitive 
TORC1 complex via inhibition of the TSC2 tumor 
suppressor, is a key pro-oncogenic function of Akt.135 
Because  H-ras  mutation  is  seldom  seen  in  human 
tumors, it will be important to determine whether Akt/
TSC/TORC1  signaling  is  similarly  required  down-
stream  from  glioma-relevant  perturbations,  such  as 
EGFR  mutation  and  overexpression  and/or  PTEN 
loss. Evidence that this may indeed be the case is 
provided by the efficacy of PI-103, a small molecule 
inhibitor  of  both  p110  and  mTOR,  which  potently 
blocks the growth of glioma cell lines and of U87EG-
FRvIII  xenografts  following  subcutaneous  injec-
tion in nude mice, without discernable toxicity to the 
animals.136 The use of TSC2−/− cells, which display 
constitutive phosphorylation of the TORC1 substrates 
S6 K1 and 4E-BP1, revealed the existence of a nega-
tive feedback loop, whereby inhibitory phosphoryla-
tion of the insulin receptor substrate (IRS-1) by S6 K1 
causes a reduction in Akt activation.137–140 Treatment of 
glioma cells with TORC1-specific inhibitors, such as 
rapamycin, disrupts such feedback control, resulting 
in increased Akt activity.136 Dual inhibition of PI3K 
and  TORC1  by  PI-103  overcomes  these  problems 
and likely explains its increased efficacy. In addition, 
phosphorylation of the FOXO transcription factors by 
Akt, which promotes their exclusion from the nucleus, 
reduces the expression of a number of important target 
genes, including the CDK inhibitors p21 WAF1/CIP1 
and p27KIP1 (both of which are also directly targeted 
by Akt) and the RB family member p130.141–143 Recent 
data on context-specific actions of FOXO on differ-
ent cell types and tissues, suggest the need to validate 
these FOXO targets in glioma.144
PI3K-MAPK-p53-RB pathway 
interactions
PI3K, MAPK, p53, and RB pathways are often con-
sidered  as  distinct  entities,  but  there  is  significant 
cross-talk among them. Such cross-talk reinforces the 
inappropriate regulation of any single pathway per-
turbation. For example, because p53 enhances PTEN 
transcription and represses the expression of p110,145,146 
the loss of p53 in cells with constitutively active RTK 
signaling, can further potentiate PI3K pathway acti-
vation. Therapies aimed at reactivating p53 in GBM, 
may be compromised by MAPK and PI3K interven-
tion in the activity of p53 and its effectors. MAPK 
signaling activates c-myc, which binds the miz-1 tran-
scriptional repressor to block p21 gene induction,147,148 Glioma growth inhibition
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while Akt impacts on p53 function by phosphorylation 
of Mdm2,149–151 in addition to the direct inhibition of 
p21. Moreover, these pathways can negate each other: 
p53  can  inhibit  activated  FOXOs  by  inducing  the 
expression of the kinase SGK1, which phosphorylates 
and exports FOXOs from the nucleus.152 Conversely, 
FOXOs  can  inhibit  p53  transcriptional  activity,  by 
increasing its association with nuclear export recep-
tors that translocate it to the cytoplasm.153 The recent 
finding that Sprouty 2, a gene involved in suppres-
sion of Ras signaling during oncogene-induced senes-
cence, is also a direct transcriptional target of FOXO, 
emphasizes the complexity of cross-talk that exists 
between the Ras/MAPK and PI3K pathways.144,154 The 
complicated interplay among these critical molecules 
highlights the need for detailed dissection of aberrant 
pathways in each tumor, to accurately guide the choice 
of combination therapies that can simultaneously tar-
get multiple pathways.
Receptor tyrosine kinases (RTKs)
Gliomas may activate receptor-driven pathways by 
different mechanisms: overexpression of both ligands 
and receptors leading to an autocrine loop, genomic 
amplification, and/or mutation of the receptor leading 
to constitutive activation in the absence of ligand. The 
EGF and platelet-derived growth factor (PDGF) path-
ways play important roles in both CNS development 
and gliomagenesis, and targeted therapy against these 
potentially  critical  signaling  pathways  is  currently 
under vigorous basic and clinical investigation.
eGFR
EGFR  gene  amplification  occurs  in  −40%  of  all 
GBMs,  and  the  amplified  genes  are  frequently 
rearranged.155–159 An EGFR mutant allele with dele-
tion of exons 2–7 (known variously as EGFRvIII, 
EGFR, or EGFR*) occurs in 20%–30% of all human 
GBM (and in 50%–60% of those that have amplified 
wild-type EGFR), making it the most common EGFR 
mutant.160,161 EGFRvIII is a highly validated glioma 
target as evidenced by the capacity of activated EGFR 
mutants to enhance tumorigenic behavior of human 
GBM cells by reducing apoptosis and increasing pro-
liferation162–165 and to malignantly transform murine 
Ink4a/Arfnull neural stem cells (NSCs) or astrocytes 
in the mouse brain.70,74 Thus, EGFR has been a prime 
target  for  therapeutic  intervention  in  GBM  with 
small  molecule  kinase  inhibitors,  antibody-based 
  immunotherapy and immunotoxins,166–169 and, more 
recently,  small  interfering  RNA  (siRNA)-directed 
neutralization of either wild-type EGFR or the unique 
junction present in the EGFRvIII allele.170,171
Transcriptional profiles of GBM with EGFR over-
expression  have  revealed  distinct  gene  expression 
profiles that have enabled classification of molecular 
subgroups  among  phenotypically  undistinguishable 
tumors.172 Along  similar  lines,  immunohistochemi-
cal studies have demonstrated that GBM could be 
stratified according to PI3K pathway activation status 
and that these activation profiles are associated with 
EGFRvIII expression and PTEN loss.173 Such efforts 
to stratify patients appear to be important in the opti-
mal deployment of small molecule EGFR inhibitors as 
only a small fraction of GBM patients show meaning-
ful responses to such agents.174,175 Thus far, in respon-
sive cases, patients with coexpression of EGFRvIII176 
or wild-type EGFR,177 together with PTEN presence 
or low Akt activation levels in their GBM cells, exhib-
ited the most favorable outcomes to EGFR inhibitors. 
In  accordance  with  findings  of  multiple  activated 
pathways in GBM, addition of the mTOR inhibitor, 
rapamycin, has been shown to enhance the sensitivity 
of PTEN-deficient tumor cells to the EGFR kinase 
inhibitor,  erlotinib.178–180  Consistent  with  enhanced 
apoptosis resistance by EGFRvIII, activated EGFR 
has  also  been  shown  to  confer  radio-  and  chemo-
resistance  to  GBM  cells.181,182  These  experimental 
observations and the capacity of EGFR inhibitors to 
sensitize GBM cells to radiation and chemotherapeu-
tic  agents,168,183,184  predict  improvent  of  therapeutic 
outcome by disruption of EGFR function at the time 
of ionizing radiation and subsequent chemotherapy, 
instead of at the time of recurrence.185 These results, 
coupled with the identification of EGFR-activating 
ectodomain  mutations  in  14%  of  GBMs  convey-
ing sensitivity to erlotinib,186 are beginning to detail 
tumor  molecular  profiles  and  therapeutic  regimens 
that will best benefit tumor patients with EGF recep-
tor and downstream pathway genetic lesions.
PDGF receptor (PDGFR)
In addition to the EGFR signaling axis, PDGFR and 
its  ligands,  PDGF-A  and  PDGF-B,  are  expressed 
in  gliomas,  particularly  in  highgrade  tumors,  and 
strong expression of PDGFR occurs in   proliferating Nieto-Sampedro et al
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  endothelial cells in GBM.187–190 PDGF-C and PDGF-D, 
which require proteolytic cleavage for activity, are also 
frequently expressed in glioma cell lines and in GBM 
tissues.191 In contrast to EGFR, amplification or rear-
rangement of PDGFR is much less common, and a 
relatively rare oncogenic deletion mutation of PDGFR 
(loss of exons 8 and 9) has been described192 that, sim-
ilar to EGFRvIII, is constitutively active and enhances 
tumorigenicity.  Given  the  tumoral    coexpression  of 
PDGF and PDGFR, autocrine and paracrine loops may 
be the primary means by which this growth factor axis 
exerts its effects. Supportive evidence for a paracrine 
circuitry initiated by PDGF-B secretion, that enhances 
glioma angiogenesis, has been shown through stimu-
lation of endothelial cells displaying PDGFR, in part, 
to express VEGF.193 Besides glial precursor cells, neu-
ral stem cells (NSCs) in the adult subventricular zone 
have been shown to express PDGFR and PDGF could 
stimulate these NSCs to form glioma-like lesions in 
the mouse.194   Furthermore, mice transgenic for neural 
progenitor PDGF-B expression resulted in the forma-
tion of oligodendrogliomas and elevation of PDGF-B 
levels  increased  overall  tumor  incidence,195,196  sug-
gesting  that  targeted  therapy  against  this  pathway 
could  have  therapeutic  potential.197 To  this  end,  an 
orally  active  kinase  inhibitor  of  the  2-phenylamin-
opyrimidine class such as STI571 (imatinib mesylate, 
Gleevec) has been shown to be a potent inhibitor of 
these oncogenic loops198,199 and, when combined with 
hydroxyurea in a phase II study, has been shown to 
achieve durable anti-tumor activity in some patients 
with recurrent GBM.200 In contrast, when used alone, 
imatinib has minimal activity on malignant glioma.201
RTK coactivation and cooperation
An explanation for the failure of EGFR and PDGFR 
inhibitors to elicit significant clinical outcomes, is that 
additional RTKs may cooperate to provide a signal-
ing threshold that prevents the inhibition of mitogenic 
and survival signals through the inactivation of any 
single RTK. This hypothesis is supported by work 
that    demonstrates  that  multiple  RTKs,  in  addition 
to EGFR and PDGFR, are activated simultaneously 
in  primary  GBM  patients.202  Oncogenic  signaling, 
survival,  and  anchorage-independent  growth,  were 
not fully abrogated until cell lines with endogenous 
coactivation  of  RTKs  were  treated  with  pharma-
cological agents or siRNAs targeting at least three 
  different receptors. The significant cross-talk among 
mitogenic pathways, serves to reinforce the inappro-
priate regulation of any single pathway perturbation. 
Importantly, these effects were observed irrespective 
of PTEN status, indicating that the presence of a tumor 
suppressor may not be a critical determinant of thera-
peutic success, as long as upstream signaling effectors 
are sufficiently inhibited. The discovery of receptor 
coactivation or cooperation suggests that tumor RTK 
profiling may be an important step in the development 
of a personalized GBM therapeutic regimen. Glioma 
cells engineered to overexpress EGFRvIII to levels 
observed  in  GBM  caused  increased  c-MET  phos-
phorylation, that was dependent on the kinase activ-
ity and levels of this mutant EGFR.203 The cross-talk 
between two receptors could be targeted with specific 
inhibitors to both, resulting in enhanced cytotoxicity 
of EGFRvIII-expressing cells, compared with either 
compound alone. It appears that the initially disap-
pointing clinical trials using RTK-targeted agents in 
GBM should be reanalyzed with respect to the RTK 
activation profiles of responders and nonresponders 
and that, when selecting combination inhibitor regi-
mens  in  future  trials,  RTK  coactivation  should  be 
taken into account.
cell Death, Migration  
and Angiogenesis
Apoptosis
A  hallmark  feature  of  malignant  glioma  cells  is  an 
intense resistance to death-inducing stimuli, such as 
radiotherapy and chemotherapy. This biological prop-
erty has been linked to genetic alterations of key regu-
latory molecules involved in mitogenic signaling, most 
prominently RTKs and the PI3K–PTEN–Akt signaling 
axis, as well as regulatory and effector molecules resid-
ing in classical cell death networks of both extrinsic 
(death receptor-mediated) and intrinsic (mitochondria-
dependent) apoptosis signaling pathways.
The “death receptors” are cell surface molecules 
that, upon binding their cognate ligands, recruit adapter 
molecules to provide a molecular scaffold for the auto-
proteolytic  processing  and  activation  of  caspases.204 
The  most  important  death  receptor  systems  include 
TNFR1  (DR1/CD120a),  TRAILR1  (DR4/APO-2), 
TRAILR2 (DR5/KILLER/TRICK2), and CD95 (DR2/
Fas/APO-1) (Fig. 5). Several lines of evidence support 
important  roles  for  these  death  receptors  in  glioma Glioma growth inhibition
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pathogenesis. First, various human glioma cell lines 
and  primary  glioma-derived  cell  cultures  are  sensi-
tive to death ligand-mediated apoptosis in vitro and in 
xenograft model systems in vivo.205–210 Second, expres-
sion levels of these death receptors and in particular 
of their corresponding (antagonistic) decoy receptors, 
seem to correlate with susceptibility of glioma cells to 
death ligand-induced apoptosis. A prominent example 
is the decoy receptor for CD95 ligand (CD95L), the 
soluble decoy receptor 3 (DcR3). It is expressed on 
malignant  glioma  cell  lines,  and  its  expression  pat-
tern correlates with the grade of malignancy in human 
glioma   specimens.211 Interestingly, infiltration of CD4+ 
and CD8+ T cells and microglia/macrophages was sig-
nificantly decreased in DcR3-driven xenografts, sug-
gesting that glioma cells escaped CD95L-dependent 
immune-cytotoxic attack by expressing a decoy recep-
tor, that neutralized CD95L by preventing its interac-
tion with the receptor.211
The TRAIL death receptor system (Fig. 5), has 
considerable interest as a specific inducer of cancer 
cell apoptosis, as its expression has been positively 
correlated  with  survival  of  patients  with  primary 
GBM.212 In this regard, loco-regional administration 
of  TRAIL  inhibited  growth  of  human  glioma  cell 
xenografts,213 and acted synergistically with chemo-
therapeutic drugs,208,210 in part through up-regulation 
of TRAIL-R2 and Bak protein and down-regulation 
of  the  caspase-8-specific  inhibitor  cFLIPs.214,215  In 
addition, peptides derived from the second mitochon-
dria-derived activator of caspases (Smac), a potent 
antagonist of members of the IAP family of caspase 
inhibitors, acted synergistically with TRAIL to induce 
tumor  cell  apoptosis  in  vitro  and  in  vivo,  without 
demonstrable neurotoxicity.216 Mechanistically, these 
peptides abrogate IAP-binding activity and, conse-
quently inhibition of effector caspase-9, caspase-3, 
and caspase-7 activity downstream from mitochon-
drial membrane disintegration. This underscores the 
importance of post-mitochondrial caspase activation 
for apoptosis propagation in glioma cell lines and its 
validity as a therapeutic target.216
The role of the Bcl-2 family in gliomagenesis and 
active cell suicide (apoptosis) has also been exten-
sively studied. The apoptosis regulators Bcl-2, BH 
(Bcl homology) are a family of evolutionarily related 
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Figure 5. The TNF-related apoptosis-inducing ligand, TRAIL. Also designated CD253, this protein, with homology to other members of the tumor necrosis 
factor superfamily, binds to the death receptors TRAIL-R2 and TRAIL-R1 and causes caspase-8-dependent apoptosis. Caspase-8 activates downstream 
effector caspases, including procaspase-3, -6, and -7, leading to activation of specific kinases.Nieto-Sampedro et al
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proteins that govern mitochondrial outer membrane 
permeabilization  and  can  be  either  pro-apoptotic 
(Bax, BAD, Bak and Bok) or anti-apoptotic (includ-
ing Bcl-2 proper, Bcl-xL, and Bcl-w, among a total 
of 25 Bcl-2 family genes known to date). The mem-
bers of the Bcl-2 family share one or more of the four 
characteristic domains of homology entitled the BH 
domains (BH1 through BH4). The BH domains are 
crucial for function and deletion of these domains by 
cloning affects survival/apoptosis. The anti-apoptotic 
Bcl-2 proteins, such as Bcl-2 and Bcl-xL, conserve 
all four BH domains. The Bcl-2 family has a general 
structure  that  consists  of  a  hydrophobic  helix  sur-
rounded by amphipathic helices.217 Many members of 
the family have transmembrane domains. The site of 
action for the Bcl-2 family is fundamentally the outer 
mitochondrial membrane.218–220 Apoptogenic factors 
within the mitochondria (cytochrome c, Smac/  Diablo 
homolog,  Omi)  if  and  when  released,  activate  the 
executioners of apoptosis, the caspases.
On the mechanistic level, classical anti-apoptotic 
Bcl-2  family  members  (BAK,  BAD,  BID,  BAX, 
BCL-XL, MCL-1) modulate apoptosis by preserving 
mitochondrial membrane integrity and preventing the 
release of cytochrome C, the caspase cascade and the 
apoptotic program.221 On the clinical level, tumor grade 
correlates with the expression of anti-apoptotic Bcl-2 
proteins (BCL-2 and MCL-1).222,223 In general, Bcl-2 
regulation is shifted toward an anti-apoptotic balance 
during the transition from initial to recurrent GBM.224 
Additionally, Bcl-XL is up-regulated by overexpres-
sion of EGFRvIII in glioma cells and this upregula-
tion confers resistance to the chemotherapeutic agent 
cisplatin.181 In addition to their classical roles, Bcl2 
family  members  may  contribute  to  gliomagenesis 
through enhancement of migration and invasion, by 
altering the expression of metaloproteinases and their 
inhibitors.225–227 Due to their central role and impor-
tance  in  apoptosis  signaling,  neutralization  of  anti-
apoptotic Bcl-2 proteins by antisense technology,228 
small  molecules  that  block  BcL2  interactions  with 
other  families,229  or  by  viral-mediated  delivery  of 
select proapoptotic members,230 may represent prom-
ising future avenues of therapeutic intervention.
Necrosis
GBM  cells  are  highly  resistant  to  therapeutic 
  apoptotic stimuli. However, they exhibit a   paradoxical 
  propensity for extensive cellular necrosis, which is 
the most prominent form of spontaneous cell death in 
GBM. It shows as foci of micronecrosis, surrounded 
by broad hypercellular zones contiguous with nor-
mal  tissue  or  parenchymal  infiltrates.231,232  Impor-
tant causes of necrosis are limited blood supply and 
anoxia, due to microthrombotic processes. These are 
the molecular bases for necrosis that, in the context of 
high apoptotic therapy resistance, has recently come 
into focus with the discovery and characterization of 
the Bcl2-like 12 (Bcl2 L12) protein.
Bcl2L12  is  a  potent  inhibitor  of  the  post-mito-
chondrial apoptosis signal transduction, that is signif-
icantly overexpressed in primary GBMs.233 Bcl2L12 
is a proline-rich protein characterized by a C-terminal 
14-amino-acid sequence with significant homology 
with BH2 domain, found in several members of the 
Bcl-2 protein family.234 Overexpression of Bcl2L12 in 
primary cortical astrocytes inhibited apoptosis, and its 
RNAi-mediated knockdown sensitized human glioma 
cell lines to drug-induced apoptosis and reduced tumor 
formation in an orthotopic transplant model in vivo.233 
The anti-apoptotic actions of Bcl2L12 relate signifi-
cantly to its capacity to neutralize effector caspase 
activity downstream from mitochondrial dysfunction 
and apoptosome activity, probably by interacting spe-
cifically with effector caspase-7.233 These activities 
of Bcl2L12 are highly relevant to the necrotic pro-
cess, considering that suppression of caspase activity 
downstream from mitochondria redirects the death 
program from apoptosis to necrosis (reviewed in),235 
indicating that post-mitochondrial caspase activation 
acts  as  a  molecular  switch  between  apoptotic  and 
necrotic cell death paradigms.235
In  support  of  this  model,  germline  deletion  of 
postmitochondrial  apoptosis  signaling  components, 
such as the caspase activator Apaf-1, or blockade of 
effector caspase maturation by pan-specific caspase 
inhibitors, results in decreased apoptosis yet causes 
increased necrosis.235 Mechanistically, oxidative phos-
phorylation and consequently intracellular ATP lev-
els, decrease due to extensive cytochrome C release 
and mitochondrial dysfunction, rendering cells unable 
to maintain ion homeostasis and provoking cellular 
edema, dissolution of organelles, and plasma mem-
branes.235 That apoptosis and necrosis signaling path-
ways are interconnected, is evidenced by the ability 
of enforced Bcl2L12 expression to provoke necrotic Glioma growth inhibition
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cell  morphology,  evidenced  by  substantial  plasma 
membrane disintegration and enhanced nuclear and 
subcellular  organelle  swelling  in  apoptosis-primed 
astrocytes.233 Therefore, up-regulation of Bcl2L12 as 
a novel regulator of the apoptosis/necrosis balance in 
glial cells, may represent an important event in malig-
nant glioma pathogenesis.
Angiogenesis
GBMs are among the most highly vascularized solid 
tumors.  Microvascular  hyperplasia  is  the  defining 
histopathological phenotype of both primary and sec-
ondary GBM. It consists of proliferating endothelial 
cells, emerging from normal parent microvessels as 
microaggregates (glomeruloid bodies), accompanied 
by stromal elements, including pericytes and basal 
lamina.236 Microvascular density, a measure of micro-
vascular proliferation, is an independent prognostic 
factor for adult gliomas.237,238 The idea that angiogen-
esis is rate limiting for tumor growth, and therefore 
a rational therapeutic target, is strongly supported by 
animal studies that have shown that angiogenesis is 
vital for macroscopic solid tumor growth.239
One common feature in the transition from low-
grade or anaplastic astrocytomas to secondary GBM, 
is a dramatic increase in microvascular proliferation 
(Fig.  1).  An  equivalently  robust  microvasculature 
proliferation phenotype is observed in primary GBM. 
Since there are marked genomic differences between 
primary and secondary GBM,240 it is likely that dif-
ferent genetic programs converge on a final common 
angiogenesis  pathway,  involving  hypoxia-inducible 
factor  (HIF)  and  non-HIF-dependent  downstream 
effectors, including positive (VEGF, PDGF, bFGF, 
IL-8, SDF-1) and negative (thrombospondin1, throm-
bospondin2, endostatin, tumstatin, interferons) regula-
tors of this process.241 A comprehensive understanding 
of the molecular mechanisms driving angiogenesis in 
GBM will be necessary for the rational development 
and deployment of anti-angiogenesis therapies. It is 
becoming increasingly evident that tumor-associated 
angiogenesis is not simply a physiological adaptation 
to hypoxia as a result of an increasing tumor cell mass. 
Rather it appears to be the result of critical genetic 
mutations that activate a transcriptional program for 
angiogenesis, with local tumor oxygen status further 
modifying this response. The relative contributions of 
these two mechanisms are not yet fully defined, but 
it is likely that both may operate to different extents 
in different tumors or even in different regions of the 
same tumor. Several experimental studies have shown 
that key glioma-relevant mutations—including those 
in the PTEN, EGFR, and CMYC genes—may act as 
an “angiogenic switch” by stabilizing HIF-1 or one of 
its downstream targets, VEGF.242–245 The distinction 
between microvascular proliferation being an adap-
tive response to hypoxia, or it being an epiphenom-
enon of critical genetic mutations that also activate 
a cascade of proangiogenesis pathways, has clinical 
and therapeutic importance.
Another issue, are the functional consequences of 
tumor angiogenesis with respect to tissue perfusion.246 
Tumor microvessels are highly tortuous, with sluggish 
flow  and  diminished  gradient  for  oxygen  delivery, 
increasing susceptibility to thrombosis and microhe-
morrhages.247  Thus,  GBM  microvasculature  prolif-
eration may provide little increase in oxygen/nutrient 
delivery, paradoxically contributing to exacerbate a 
metabolic mismatch between “supply and demand,” 
leading to progressive hypoxia and eventual   necrosis. 
This  scenario  is  supported  by  the  experience  with 
anti-angiogenesis drugs, where their limited clinical 
benefit seems to be the result of “pruning” immature 
vessel growth and allowing “normalization” of the 
pre-existing  vasculature.248  In  addition  to  the  poor 
vascular architecture, endothelial cells associated with 
tumor vessels fail to form tight junctions and have 
few associated pericytes or astrocytic feet, compro-
mising the integrity of the BBB, increasing interstitial 
edema.  Interstitial  edema  may  further  compromise 
regional blood flow and exacerbate tumor hypoxia, 
leading to areas of necrosis. In addition to these mal-
adapted biophysical properties of GBM microvascu-
lature, specific genetic mutations in GBM probably 
contribute to compromised tumor bioenergetics, spe-
cifically the shift in energy production from oxidative 
phosphorylation to glycolysis.249,250 These interrelated 
mechanisms lead to a level of metabolic demand that 
exceeds the ability of the cerebrovascular system to 
maintain adequate blood flow to prevent hypoxia and 
necrosis.
Anti-angiogenesis therapies
The  hypothesis  that  interruption  of  blood  supply 
to the tumor will cause the regression or dormancy 
of the tumor, has led to the development of several Nieto-Sampedro et al
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drugs,  that  target  multiple  steps  in  angiogenesis 
(Table 1). Three approaches, in advanced stages of 
clinical testing, aim to target VEGF/VEGFR signaling 
pathways: (1) monoclonal antibodies against VEGF 
or its receptor(s);251–253 (2) small molecule inhibitors 
of VEGFR-2 tyrosine kinase activity,254 and (3) solu-
ble decoy receptors created from VEFGR1 receptor, 
that selectively inhibit VEGF.239 Two new approaches, 
one of them targeting V3 and V5 integrin receptors 
on  endothelial  cells255  and  another  using  umbilical 
cord blood stem cells256 are also being tested as anti-
angiogenesis therapy for GBM. Inhibition of glioma 
angiogenesis by human umbilical cord blood stem 
cells (hUCBSC), has been tested in vitro and in nude 
mice. Downregulation of FAK gene is correlated with 
downregulation of many angiogenesis-related genes, 
including Ang1, VEGFA and Akt. Neovasculariza-
tion and intracranial tumor growth of glioma cells 
in   athymic mice was inhibited by hUCBSC in vivo. 
Similar to in vitro results, downregulation of FAK, 
VEGF and Akt molecules was observed, leading to 
inhibition of angiogenesis in hUCBSC-treated mice 
brains.  Therefore,  hUCBSC  have  the  potential  to 
inhibit growth of glioma both in vitro and in vivo.256
Clinical studies that used anti-angiogenesis drugs 
as “single” agents to treat GBM, have shown little 
efficacy. This may reflect the fact that these drugs have 
no direct effect on the pre-existing stable microvascu-
lature that may be co-opted to support tumor growth, 
especially at the infiltrating tumor edge. Recent data, 
however, suggest that anti-  angiogenesis drugs may be 
more effective when combined with cytotoxic therapy 
(Table 1). Recently a phase II study of bevacizumab 
(Avastin; Genentech, Inc.),253 a recombinant human-
ized monoclonal antibody targeting VEGF, plus irino-
tecan (CPT-11) in patients with recurrent high-grade 
gliomas,  reported  dramatic  rates  (63%)  of  radio-
graphic response and a near doubling of 6 month and 
median progression free survival (PFS) in patients with 
GBM (30% and 20 week, compared with   historical 
Table 1. examples of targeted therapies for cancer.
Drug in clinical use commercial name Drug target cancer type
Bevacizumab Avstin veGF Colorectal, breast, lung, renal
Bortezomib velcade Proteasome Myeloma, lymphoma
Colecoxib Onsenal COX 2 Adenomatous polyposis
erlotinib Treceva
Gefitinib Iressa
Cetuximab erbitux eGFR Colrectal, lung, head and neck
Panitumumab vectibix
RAD 001 Certican
Temirolimus Torticel mTOR Renal
Imatinib Gleevec
Dasatinib Sprycel PDGFR, BCR ABL, Leukemia, gastrointestinal
Nilotinib Tasigna cKIT
Sorafenib Nexavar veGFR, RAF, cKIT, Renal, hepatic
Sunitinib Tasigna PDGFR
Topotecan
Irinotecan
Hycamtin
camptosar
Topoisomerase I Multiple cancer types
Trastuzumab Herceptin eRBB2
Lapatinib Tykerb HeR2, eGFR
Tamoxifen Nolvadex eRα
exemestane Aromasin Aromatase cytochrome P450 Breast
Anastrozole Arimidex
Letrozole Femara
Rituximab MabThera
Tositumomab Bexxar CD20 Lymphoma
Abbreviations: BCR-ABL, fusion protein of breakpoint cluster region and tyrosin kinase ABL 1; CD20, B-cell phosphoprotein CD20; c-KIT, tyrosine kinase 
cKIT; COX-2, cyclooxygenase 2; eGFR, epidermal growth factor receptor; eRα, estrogen receptor α; eRBB2, erythroblastic leukemia viral oncogene 
homolog 2; ΗΕR _epidermal growth factor receptor 2; mTOR, mammalian target of rapamycin; PDGFR, platelet-derived growth factor receptor; RAF, small 
GTPase RAF; veGF, veGFR, vascular endothelial growth factor, receptor.Glioma growth inhibition
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  controls of 15% and 9 week). The   therapeutic   benefits 
in  the  setting  of  combination  therapy  (radiation 
and/or   conventional chemotherapy) could be attributed 
to: (1) improved drug delivery, because of improved 
blood flow; (2) improved drug penetration into the 
tumor, because of reduced interstitial pressure, and/
or (3) improved radiation/chemotherapy response, as 
a result of reducing tumor hypoxia. Hypoxia is well 
known to create radiation resistance and reduce effi-
cacy of chemotherapies.257 Overall, the clinical data 
for the anti-angiogenic drugs, when used in combina-
tion with radiation or conventional chemotherapies, 
are encouraging. The possibility that anti-angiogenic 
drugs  may  enhance  intratumoral  concentration  of 
conventional  chemotherapeutics,  raises  the  intrigu-
ing possibility that these drugs may improve the effi-
cacy profile of some available antimitotics. A possible 
mechanism for such synergy could be enhanced drug 
delivery, although off-target drug effects and/or poorly 
understood pharmacological mechanisms remain pos-
sible. The full benefit of anti-angiogenesis will derive 
from  an  improved  understanding  of  the  molecular 
basis of tumor angiogenesis, how tumor cell metabo-
lism drives angiogenesis versus cooptation of normal 
brain microvascular networks, and definition of those 
patients that are likely to benefit from various types of 
anti-angiogenic therapies operating on different levels 
of the process.
GBM can be roughly separated into an angiogenic 
component, and an invasive or migratory component. 
Although the latter component seems insensitive to 
anti-angiogenic therapy, it is of major importance for 
disease progression and survival. Clinical symptoms 
seem  to  be  tempered  by  anti-angiogenic  treatment, 
but  tumour  invasion  continues.  Unfortunately,  cur-
rent imaging modalities are affected by antiangiogenic 
treatment too, making it very hard to define tumour 
margins, as shown by MRI, biopsy and autopsy of bev-
acizumab-treated patients. Moreover, while treatment 
of other tumour types may be improved by combin-
ing chemotherapy with anti-angiogenic drugs, inhibit-
ing angiogenesis in GBM may antagonise the efficacy 
of chemotherapeutic drugs by normalising the blood-
brain barrier function.258 In summary, although angio-
genesis inhibition is of considerable value for symptom 
reduction in GBM patients, lack of proof of a true anti-
tumour effect has raised concerns about the place of 
this type of therapy in the treatment of GBM.
Tumor cell invasion
Infiltration throughout the brain is prominent in low- 
and high-grade malignant glioma259 and is the prin-
cipal reason for the failure of surgical cure. In more 
than 90% of the cases, the recurrent tumor develops 
  immediately adjacent to the resection margin or within 
several centimetres of the resection cavity. Invasion 
by glioma cells into regions of normal brain is driven 
by a process involving cell interactions with the ECM 
and with adjacent cells, as well as biochemical pro-
cesses supportive of proteolytic degradation of ECM 
and active cell movement. These processes bear a 
striking resemblance to the robust intrinsic migration 
potential of glial cells during embryogenesis.260
The most frequent route of invasion of glial tumor 
cells is along white matter tracts and basement mem-
branes of blood vessels. Whether this route offers a 
path of least resistance or there are biochemical sub-
strates that mediate adhesion and promote migration, 
or both, is unclear. Invasion and migration of glial 
tumors differs from other tumors where local spread 
is  very  limited  and  dissemination  occurs  hematog-
enously or via the lymphatic system. In fact, glioma 
cells lack the ability to penetrate the basement mem-
brane of blood vessels,261 and cells gaining access to 
the blood through a disrupted blood vessel within the 
tumor  are  unable  to  establish  robust  tumor  growth 
outside the CNS. The molecular basis for this curious 
inability of glioma cells to metastasize outside of the 
CNS is not known and warrants further investigation.
Several  genes  involved  in  glioma  invasiveness 
have been identified, including members of the fam-
ily of metalloproteases (MMP) and their endogenous 
tissue inhibitors (TIMPs). Expression of MMP-2 and, 
to a lesser extent, MMP-9 correlate with invasiveness, 
proliferation and prognosis in astrocytomas.262 Other 
non-MMP proteases, including urokinase-type plasmi-
nogen activator (uPA)263–265 and cysteine proteases (eg, 
cathepsinB),266 are elevated in high-grade malignant 
gliomas.267 Despite these findings, the role of proteases 
in glioma invasion remains unclear, since low-grade 
astrocytomas infiltrate diffusely throughout the brain, 
despite their relatively normal levels of proteases.
Integrins, especially V3 complexes, are elevated in 
GBM and appear to be relevant to processes of glioma 
invasion  and  angiogenesis.268  Several  studies  have 
also reported potential novel glioma invasion genes. 
  Invasion inhibitory protein 45 (IIp45), a potential tumor Nieto-Sampedro et al
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suppressor gene on chromosome 1p36, is frequently 
down-regulated in GBMs. Its product inhibits invasion 
through the binding of IGFBP2.269 In contrast, IGFBP2 
promotes invasion in GBM by up-regulating a panel of 
genes involved in invasion, one of which is MMP-2.270 
Other proteins are overexpressed in invasive areas of 
GBM, such as angiopoietin-2, which in addition to its 
involvement in angiogenesis also plays a role in induc-
ing  tumor  cell  infiltration  by  activating  MMP-2.271 
  Ephrin receptors and their ligands, the ephrins, mediate 
neurodevelopmental processes such as axon guidance 
and cell migration and regulate migration and invasion 
of glioma. Compared with low grade astrocytoma or 
normal brain, GBMs migratory tumor cells overexpress 
EphB2,271 which has been linked to poor survival.272
Other novel invasion- and migration-associated genes 
have been identified using oligonucleotide microarray 
technology273,274  on  RNA  isolated  by  laser-captured 
microdissection of cryostat sections from human glioma 
biopsy tumor cores and invasive edges. These genes 
include P311, a 68-amino-acid polypeptide described 
in  embryonic  neuronal  migration;  death-associated 
protein  3  (DAP3),  which  conferred  protection  from 
Fas-induced, ionizing radiation-induced, and streptoni-
grin-induced cell death;275 and FN14, which encodes a 
cell surface receptor for the tumor necrosis factor super-
family member named TWEAK, all of which modulate 
glioma cell migration and apoptosis.276–278
Since migrating glioma cells show increased levels 
of phosphorylated Akt, PI3K inhibitors have been tested 
experimentally on these cells, resulting in a decrease in 
migration and increased apoptosis sensitivity.279 In con-
junction with this, a PTEN mutation has been impli-
cated in an invasive phenotype, not only as contributing 
to deregulated PI3K signaling, but also in its ability to 
stabilize E-cadherin and modulate cell matrix adhesion 
complexes.280 These findings highlight the multitude of 
ways in which glioma adopt a broad spectrum of the 
tumor phenotypes, ranging from aberrant cell prolifera-
tion to invasion and resistance to apoptosis.
Glioma chemotherapy, 
Immunoresistance
Glioma, blood-brain barrier  
and immunoresistance
Untreated, GBM patients survive less than 6 months. 
Even after intensive therapy, combining gross total 
resection,  radiation,  and  chemotherapy,  the  mean 
  survival time is only 14 months. The lack of effectivity 
of standard therapies is due to several reasons, includ-
ing robust tumour cell proliferation, neo-angiogenesis, 
genetic instability, and immunosuppression. A factor 
that contributes to GBM malignancy is its high degree 
of genetic instability, that generates cellular heteroge-
neity. The various cell types in a glioma population 
do not respond equally to radiation and chemotherapy, 
causing further relapses. In addition, chemotherapy 
has generally been unsuccessful because of poor drug 
delivery. The presence of active efflux transporters in 
the blood-brain barrier (BBB), prevents systemically 
administered drugs from entering the brain, highlight-
ing the need for new comprehensive strategies to over-
come this functional obstacle.
A most important and lethal property of gliomas 
is their immune invisibility. Malignant brain gliomas 
are able to evade and suppress the immune system. 
Glioma evasion from the immune system occurs at 
different levels of antigen recognition and immune 
activation.281–284 First, by limiting effective signaling 
between glioma and host immune cells, glioma cells 
evade immune detection. An important component of 
this efficient immune escape is the complexity of the 
self-sustaining  glioma  microenvironment.  Gliomas 
generate  several  immunosuppressive  mechanisms 
(Fig.  6)  that  acting  simultaneously,  create  positive 
feedback loops that enhance their effects.281–284
In order to evade immune detection, many glioma 
cells express low levels of human leukocyte antigens 
(HLA; major histocompatibility complex, MHC) or 
express defective MHC.285 A recent report by Facoetti 
and colleagues286 described that approximately 50% 
of 47 glioma samples had lost MHC type I antigen. 
Among these, 80% showed evidence of selective loss 
of HLA-A2 antigen. It should be noted that loss of 
HLA type I antigen was more common with higher 
grade tumors, suggesting a role of deficient antigen 
presentation in glioma progression. Inhibition of anti-
gen presentation by microglia and macrophages in 
the tumor microenvironment, also contributes to the 
tumors’ ability to escape immune detection (Fig. 6). 
The presence of glioma cells caused monocytes to 
reduce their phagocytic activity in vitro.287 In addi-
tion, microglia found within glioma tissue appeared 
deficient  in  proper  antigen  presentation  for  cyto-
toxic and helper T-cell activation.288 Schartner and Glioma growth inhibition
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  colleagues289  demonstrated  that  MHC-II  induction 
by stimulation was significantly less in microglia and 
infiltrating macrophages derived from gliomas than 
in those isolated from normal brain.
The CNS is considered immune privileged relative 
to other organs, by the virtue of the BBB restricting 
the migration of immune cells and cytokines into the 
brain, the absence of a lymphatic drainage system, 
the presence of a high concentration of immunosup-
pressive  factors,  and  the  lack  of  major  histocom-
patibility  complex  (MHC)  molecule  expression  in 
normal  CNS  cells.  However,  newer  data  indicate 
that the CNS is a perfectly adequate environment for 
immune responses, as evidenced by the presence of 
both humoral and cell-mediated CNS immunity.290–292 
In addition, lymphocytes have been shown to traffic 
to normal brain (both naive lymphocytes and acti-
vated T cells)293 by crossing the BBB without antigen 
specificity.293–295 Furthermore, many types of lympho-
cytes appear in the CNS during illness, such as infec-
tion or autoimmune processes.296–298
Many tumors, including GBM, create an immuno-
suppressive  local  environment  to  shield  themselves 
from the body’s normal immune response. The immune 
microenvironment created by GBM likely plays a much 
larger role in immune evasion than the general BBB, 
which  is  typically  compromised  by  the  tumor. The 
strategies used by GBM to evade the immune   system 
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Figure 6. Strategies used by glioma cells to evade host immune system. Glioma inhibited T-cell activation and proliferation by interfering with antigen 
presentation. Antigen presenting cells (APC) expressed MHC and B7 costimulatory molecules. The interaction via T-cell receptors permitted to identify 
antigens as self or foreign. when T cells identify non-self-antigens, they activate and proliferate, mounting an immune response. This interaction is dis-
rupted by tumors, that cause downregulation of MHC expression. Loss of MHC molecules blocks the cross talk between tumor cells and the immune cells 
responding to the tumor. Downregulation of the costimulatory molecules, B7.1 and B7.2, induce T-cell anergy. Upregulation of inhibitory B7 molecules, 
such as B7-H1, or death signals, such as FasL, cause T-cell apoptosis.Nieto-Sampedro et al
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include : (1) aberrant antigen recognition, leading to 
insufficient immune cell activation, (2) promotion of 
suppressor immune cells, inducing T-cell tolerance or 
apoptosis, (3) upregulation of co-inhibitory molecules, 
(4)  secretion  of  immune  inhibiting  molecules,  (5) 
recruitment of suppressor immune cells, and (6) acti-
vation of immunosuppressive pathways.
Glioma-induced abnormalities in antigen 
recognition and immune cell activation
One mechanism by which GBM evades the immune 
system is by preventing normal antigen recognition, 
a process orchestrated by the major histocompatibil-
ity complex (MHC). The MHC, known in humans as 
human leukocyte antigen (HLA), displays fragmented 
pieces of self or non-self-antigens on the surface of 
host antigen presenting cells. Normally, T cells inter-
act with MHC via T-cell receptor molecules, to deter-
mine if the antigen is self or foreign. A second signal, 
the costimulatory signal, is also required for T cells to 
become fully activated. If this process occurs prop-
erly, T cells will react appropriately to foreign pep-
tides and ignore self-peptides (Fig. 6).
Parney and colleagues299 found that most GBM 
expressed low levels of class I MHC and no class 
II MHC. These data were supported by Lampson’s 
finding that class I MHC could be upregulated in 
gliomas after interferon γ (IFNγ) exposure in   vitro.300 
There are several reasons why class I and class II 
MHC molecules are not expressed on the glioma cell 
surface. First, gliomas have been reported to express 
immunoinhibitory  factors,  such  as  transforming 
growth  factor  β  (TGF-β)301  and  prostaglandin  E2 
(PGE2),302 that downregulate class II MHC on glioma 
cells (Fig. 6). Second, most GBM lesions express 
mutated class I HLA molecules. Loss of HLA class 
I antigen significantly correlates with tumor grade3 
and with tumors refractory to immunotherapy.303 The 
components  of  the  antigen  processing  machinery 
(APM) were also investigated, and tapasin expres-
sion was found to be downregulated in GBM lesions. 
Tapasin  is  an  endoplasmic  reticulum  (ER)  mole-
cule uniquely dedicated to tether HLA class I mol-
ecules, jointly with the chaperone calreticulin (Crt) 
and  the  oxidoreductase  ERp57,  to  the  transporter 
associated with antigen processing (TAP).304 These 
changes seem to be linked with mutations of HLA 
class I antigen expression, and significantly correlate 
with the clinical course of the disease. Mutations in 
HLA class I antigen and in APM components may 
provide a mechanism for GBM to escape immune 
recognition and killing by cytotoxic T lymphocytes 
(CTLs). These findings emphasize the need to moni-
tor expression of HLA class I antigen and APM com-
ponents in GBM lesions, when selecting patients for 
T-cell–based immunotherapy treatment.
Co-stimulatory molecules
Co-stimulation of T-cells is necessary for their pro-
liferation,  differentiation,  and  survival.  Activation 
of T cells without co-stimulation may lead to T-cell 
anergy, T-cell deletion, or development of immune 
tolerance.  CD28,  one  of  the  best  characterized 
costimulatory molecules expressed by T cells, inter-
acts with CD80 (B7.1) and CD86 (B7.2) on the mem-
brane  of  antigen  presenting  cells  (APCs).  Besides 
expressing low levels of MHC peptide (Fig. 6), can-
cer cells downregulate the co-stimulatory molecules 
required  for  activating  a  proper  immune  response. 
Lack of T-cell co-stimulation is another mechanism 
used by GBM to avoid immune surveillance. So far, 
B7 molecule expression has been found to be absent 
from glioma cells.305 In addition, peripheral blood T 
cells from patients with glioma typically show a high 
degree of anergy to GBM antigens that results from 
the absence of co-stimulatory molecules (see Fig. 6). 
The  receptors  for  the  co-stimulatory  molecules  on 
tumor-infiltrating APCs are downregulated. Human 
glioma-infiltrated microglia or macrophages (GIMs) 
completely lack CD80/CD40 expression and show 
minimal CD86 expression, which could explain their 
inability to properly activate naive T cells.306 GIMs 
from brain tumors in intracranial RG2 glioma-bear-
ing rodents, responded differently to general activa-
tors, such as CpG oligodeoxynucleotides (CpG ODN) 
and IFNg/lipopolysaccharide (LPS), when compared 
with GIMs from normal brain. CpG ODN induced 
the upregulation of B7 molecules but had little effect 
on MHC-II expression, whereas IFNg/LPS had the 
opposite effect. Both upregulations were significantly 
lower in tumor-associated GIMs, in comparison with 
GIMs from normal brain. Further studies are neces-
sary to understand if these diminished effects result 
from local GBM immunocompromising environment, 
abnormal signaling, or mutated receptor expression 
on the tumor-infiltrating GIMs.289Glioma growth inhibition
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The  B7  costimulatory  family  includes  activat-
ing and inhibiting molecules that regulate immune 
response positively and negatively. Among the latter 
group, B7-H1, one of the newly identified B7 fam-
ily members, provides negative signals that control 
and suppress T-cell responses.307 The regulation of 
B7-H1 seems to be pivotal in shaping the immune 
response to tumors, because it can exert costimula-
tory and immune regulatory functions.308 Although 
B7-H1  has  been  shown  to  mediate  tumor  evasion 
by binding to programmed death-1 (PD-1) receptor, 
additional counter receptors can also control the func-
tions of B7-H1.309 Human and rodent cancer cells and 
immune cells in the cancer microenvironment, have 
been shown to upregulate expression of inhibitory 
B7 molecules. Analysis of multiple glioma cell lines 
and human specimens have also shown high levels 
of B7-H1 (Fig. 1D).305,310 This high level of expres-
sion  reduces  glioma  cell  immunogenicity  by  sup-
pressing T-cell cytokine production and activation. 
A study by Parsa and colleagues311 demonstrates a 
potential relationship between B7-H1 and the phos-
phatase  and  tensin  homolog-phosphatidylinositol 
3-kinase (PTENPI3K) pathway. The loss of PTEN 
and the activation of the PI3K-pathway, leading to 
elevated  post-transcriptional  expression  of  B7-H1, 
is a new mechanism of immunoresistance mediated 
by B7-H1, further demonstrating the importance of 
this molecule in tumor evasion of immune surveil-
lance.311 B7-H1 correlates with the malignancy grade 
of gliomas.312 These studies demonstrate the poten-
tial benefits of using neutralizing antibodies specific 
for B7-H1 and PD-1 in the treatment of patients with 
malignant brain tumors.
Glioma-induced deregulation  
of cell-mediated immunity
Many  studies  of  patients  harboring  glioma,  per-
formed during the past 3 decades, revealed that these 
individuals exhibit a broad suppression of cell medi-
ated immunity (Fig. 6). The immune cells from GBM 
patients appear to behave in a manner reminiscent 
of autoimmune diseases, showing cutaneous anergy 
to  common  bacterial  antigens,313  lymphopenia,314 
impaired  antibody  production,  and  abnormal 
delayed-type  hypersensitivity  response  to  common 
recall antigens or neoantigens in vivo.314,315 It seems 
that the lymphocytes of patients with GBM present 
intrinsic cellular abnormalities that render potentially 
reactive T cells unresponsive. Peripheral blood lym-
phocytes (PBLs) from patients with GBM did not 
proliferate or proliferated minimally in response to 
mitogen stimulation in vitro. Elliott and colleagues 
showed that PBLs obtained from patients with GBM 
have approximately 6 times fewer phytohemaggluti-
nin (PHA)-responsive cells than PBLs from normal 
subjects.315 These lymphocytes failed to expand into 
a pool of proliferating cells in vitro. In addition, the 
supernatant  fluids  of  PHA-stimulated  lymphocytes 
obtained from patients, showed a substantial reduc-
tion of interleukin-2 (IL-2) and IFNγ, compared to 
lymphocytes  obtained  from  normal  donors.  More-
over, T cells obtained from patients with GBM were 
unable to offer helper activity in allogeneic pokeweed 
mitogen  cultures  in  vitro.316–318  This  comprehen-
sive depression in cellular immune function was not 
typical of head trauma, or other tumors of the brain. 
Hence, it must be the complex GBM tumor microen-
vironment  that  compromised  T-cell  compartments 
and their functions.
In addition to alterations in the intrinsic activation 
pathways in T cells, GBM also induced accumulation 
of immunosuppressive cells in its microenvironment. 
GBM promoted impaired immunocompetence, using 
normal  immunosuppressive  mechanisms  involv-
ing enhanced proliferation of the regulatory T cells 
(Treg). Tregs play an indispensable role in maintain-
ing immunological unresponsiveness to self-antigens 
and in suppressing excessive immune responses, del-
eterious to the host. In vivo depletion of Treg cells 
caused severe autoimmune disease, which could be 
reversed by reconstitution.319 Moreover, the regres-
sion  of  tolerogenic  tumors  after  depletion  of Treg 
cells has been observed in vivo.320
Fecci  and  colleagues321  reported  an  unbalanced 
ratio between CD41 T cells and Treg cells in GBM. 
Although  both  fractions  were  greatly  reduced  in 
patients with malignant glioma, Treg cells often rep-
resented most of the CD4 population. It is well known 
that Tregs can inhibit T-cell activation and prolifera-
tion  by  downregulating  IL-2  and  IFNγ  production 
in  the    target  cells.286,289,305,319,322,323  This  would  also 
explain the shift from TH1 to TH2 cytokines, which 
propagate the regulatory phenotype. As a demonstra-
tion of this, depletion of Tregs in vitro reestablishes 
the  normal  CD4  functions  of  the  T  cells  isolated Nieto-Sampedro et al
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from patients with GBM and reverses the cytokine 
  production to the TH1 type.321 Tumor tolerance induced 
by Tregs is common in solid tumors other than GBM. 
In addition to Treg cells, there are other suppressive 
cell types in the tumor microenvironment. Recruit-
ment of suppressive myeloid cells, such as regulatory 
dendritic cells (DCs), characterized by indoleamine-
pyrrole 2,3 dioxygenase expression324 and myeloid-
derived suppressor cells at the tumor site, is another 
way of inhibiting immune responses.325
Glioma therapies: combined surgery, 
radiotherapy and chemotherapy
Any disease with an incidence of less than 50/100000 
is defined as an orphan disease. There are some 5,000 
orphan diseases and about 8% of the population are 
affected by these disorders. Orphan diseases are, by and 
large, disregarded by pharmaceutical companies, as the 
predictable financial incentive is small. Glioblastoma 
multiforme (GBM), the most common primary tumors 
of the central nervous system (CNS) in adults,326 with 
an incidence of about 5 per 100,000 belongs to this 
group of diseases.327 GBM, WHO grade IV, accounts 
for approximately 50% of all glial tumor types and 
shows a median survival of less than one year.326,328
Radiation, introduced some 30 years ago, was the 
first addition to surgery to treat glioma. The techniques 
have changed, so that radiation can be directed much 
more  precisely  at  the  tumour,  sparing  uninvolved 
brain tissue. However, the value of radiation alone is 
quite limited, extending life only for a few months.
Chemotherapy,  involving  various  agents  over 
the  years,  has  been  added  next.  The  current  drug 
of  choice  is  temozolomide  (Temodar),329,330  an  oral 
drug that alters tumoral DNA, inducing tumour cell 
death.  However,  intense  temozolamide  chemother-
apy, increased the mutational load within the cancer 
genome  17-fold  in  comparison  to  untreated  GBM 
cells.29 We have already mentioned anti-angiogenesis 
therapy. Recently, bevacizumab, a monoclonal anti-
body  against  VEGF331  used  to  treat  other  types  of 
cancer (Avastin), has earned FDA approval for use 
in brain tumours. Avastin affects tumour blood ves-
sels, rather than the tumour cells251,332 and it is still too 
early to say whether this therapy will be a significant 
advance. While therapy directed against tumour blood 
vessels may limit tumoral growth, its efficacy against 
the  invading  tumour  cells  is  unclear.333  The    latest 
recruit to the anti-glioma army is a neuronal micro 
RNA, mR-326.334 MicroRNA-326 was downregulated 
in gliomas via decreased expression of its host gene. 
Transfection of microRNA-326 into both established 
and stem cell-like glioma lines was cytotoxic.
Unfortunately, chemotherapy can also contribute 
to inhibit the immune response to the tumor. Thus, 
temozolomide can cause CD41 lymphopenia,335 which 
may negatively affect immunotherapeutic approaches 
that use a CD41 T-cell response. The current state of 
glioma therapy, in the best medical centers, include 
the conventional approaches of surgery, radiation and 
chemotherapy. However, this multimodal treatment 
still offers a poor prognosis for GBM patients. The 
therapeutic challenge now is to block the aberrant 
and complex individual signaling network present in 
most GBM. Given the extreme adaptability of GBM 
cells, the therapeutic challenge has to lead to tumor 
cell death, preventing sublethal hits of tumor cells 
leading to the growth of more malignant clonal cell 
populations.  This  crucial  requirement  explains  the 
limitations of antiproliferative and antiangiogenetic 
approaches as therapies. Notwithstanding, blocking 
simultaneously proliferation and angiogenesis can be 
a powerful additive pro-apoptotic approach.
Glioblastoma subtypes and treatments 
adjusted to genomic abnormalities
The diagnosis of brain tumors has been based on a com-
plete clinicopathological assessment. This approach 
has permitted the distinction of different grades within 
categories of the same tumor type, such as astrocy-
tomas, that have predictive value in determining clini-
cal outcome. It has become evident from genetic and 
patient outcome studies, that subgroups are present 
within each grade. Large-scale gene expression pro-
file studies in glioblastoma have demonstrated that 
transcriptional  profiles  reflect  the  underlying  tumor 
biology. This can be used to predict tumor classifi-
cation (eg, being a surrogate for pathological grad-
ing), patient outcome, and response to treatment. An 
additional outcome of these investigations has been 
to realize that each tumor is unique in its expression 
profile, and therefore biology, suggesting that medi-
cine needs to become more personalized. Although 
that is a distant goal, it was clear from these studies 
that it was already possible to cluster the profiles from 
glioblastoma patients into molecular subtypes defined Glioma growth inhibition
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by combinations of genes that were over- or under-
expressed  within  each  group. The  Cancer  Genome 
Atlas Network (CGAN) was established to generate 
a  comprehensive  catalogue  of  genomic  abnormali-
ties driving tumorigenesis. CGAN provided a detailed 
view of the genomic changes in a large GBM cohort, 
containing  206  patient  samples.  Sequence  data  of 
91 patients and 601 genes were used to describe the 
mutational spectrum of GBM, confirming previously 
reported  TP53  and  RB1  mutations  and  identifying 
GBM-associated  mutations  in  such  genes  as  phos-
phatidyl inositol kinase regulatory subunit (PIK3R1), 
neurofibromatosis  type-1  (NF1),  and  erythroblastic 
leukemia viral oncogene homolog (ERBB2).24 Based 
on gene expression and integrated multidimensional 
genomic data, GBM were classified into Proneural, 
Neural, Classical, and Mesenchymal subtypes, estab-
lishing patterns of somatic mutations and DNA copy 
number.  The  classical,  mesenchymal,  and  proneu-
ral types depended on aberrations and gene expres-
sion  changes  of  epidermal  growth  factor  receptor 
(EGFR), NF1, and PDGFRA/IDH1 (platelet derived 
growth factor receptor alpha/isocitrate dehydrogenase 
1), respectively. Gene signatures of normal brain cell 
types showed a strong relationship between subtypes 
and neural lineages. The various subtypes differred in 
their response to aggressive therapy, the classical sub-
type receiving the greatest benefit and the proneural 
subtype showing no benefit.413 The work of Verhaak 
et al413 expanded on previous glioblastoma classifica-
tion studies, associating known subtypes with specific 
alterations in NF1 and PDGFRA/IDH1 and identify-
ing two additional subtypes, one of which is charac-
terized by EGFR abnormalities and wild-type p53. In 
addition, subtypes had specific differentiation charac-
teristics that, combined with data from mouse studies, 
suggested a link to alternative cells of origin.
To gain insight into the biological meaning of the 
subtypes, Verhaak et al336 used the data from the brain 
transcriptome database of Cahoy et al,337 to define 
gene sets associated with neurons, oligodendrocytes, 
astrocytes, and cultured astroglial cells. These mature 
cells may be of interest both, for their primary asso-
ciations with tumor subtypes, as well as for the inher-
ent signatures retained from progenitor cells. Using 
these four gene sets, a single-sample gene set enrich-
ment analysis score was calculated for all samples.338 
The  enrichment  score  indicates  the  closeness  in 
  expression of a sample to the expression pattern of a 
gene set. In their exploratory analysis, Verhaak et al336 
observed a number of patterns associating each sub-
type with expression patterns from purified murine 
neural  cell  types.  The  proneural  class  was  highly 
enriched with the oligodendrocytic signature but not 
the astrocytic signature, whereas the classical group 
was strongly associated with the murine astrocytic 
signature. The neural class showed association with 
oligodendrocytic  and  astrocytic  differentiation,  but 
also showed strong enrichment for genes differen-
tially expressed by neurons. The mesenchymal class 
was strongly associated with the cultured astroglial 
signature. Interestingly, the majority of immortalized 
cell lines evaluated showed expression patterns most 
similar  to  the  mesenchymal  subtype. Additionally, 
well-described  microglia  markers,  such  as  CD68, 
PTPRC (protein tyrosine phosphatase receptor type 
C), and TNF, were highly expressed in the mesen-
chymal class and the set of murine astroglial samples. 
Together, these data provide a framework for investi-
gating targeted herapies.
Concerns about anti-angiogenic and 
targeted therapies in GBM patients
GBM growth can be roughly separated into an angio-
genic component, and an invasive or migratory com-
ponent. Although the latter component seems inert to 
anti-angiogenic therapy, it is of major importance for 
disease progression and survival.258 Although clinical 
symptoms are tempered by anti-angiogenic treatment, 
tumour  invasion  continues.  GBM  patients  benefit 
greatly from angiogenesis inhibition, because it reduces 
cerebral oedema and intracranial pressure. However, 
on its own, anti-angiogenesis cannot be considered as 
an effective anti-tumour treatment. Multiple angiogen-
esis inhibitors have been therapeutically validated in 
preclinical cancer models, and several in clinical trials. 
Páez-Ribes et al reported339 that angiogenesis inhibi-
tors targeting the VEGF pathway, showed antitumor 
effects in mouse models of pancreatic neuroendocrine 
carcinoma and glioblastoma. However, those inhibitors 
concomitantly elicited tumor adaptation and progres-
sion to stages of greater malignancy, with heightened 
invasiveness and in some cases increased lymphatic 
and distant metastasis. Increased invasiveness is also 
seen after genetic ablation of the Vegf-A gene, substan-
tiating the results of the   pharmacological inhibitors. Nieto-Sampedro et al
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The realization that potent angiogenesis inhibition can 
alter the natural history of tumors by increasing inva-
sion and metastasis, has important implications for the 
development of enduring antiangiogenic therapies and 
warrants further investigation.
The invasive and migratory components of GBM 
are not affected by anti-angiogenic therapy. Although 
anti-angiogenic treatment relieves clinical symptoms, 
tumour invasion continues. Unfortunately, antiangio-
genic  treatment  affects  current  imaging  modalities, 
making it harder to define tumour margins.258   Moreover, 
while treatment of other tumour types may be improved 
by  combining  chemotherapy  with  anti-angiogenic 
drugs, inhibiting angiogenesis in GBM may antago-
nize the efficacy of chemotherapeutic drugs, by nor-
malizing the blood-brain barrier. Thus, angiogenesis 
inhibition is of considerable value in GBM patients for 
symptom reduction, but lack of proof of a true anti-
tumour effect raises concerns about the place of this 
type of therapy in the treatment of GBM.
Gefitinib and erlotinib are small molecule inhibi-
tors belonging to the newly named “targeted thera-
pies”, designed to inhibit the epidermal growth factor 
receptor (EGFR) tyrosine kinase.340 Clinical trials have 
shown their effectiveness for the treatment of patients 
with advanced non-small cell lung cancer. They have 
been  considered  as  relatively  safe  agents,  common 
adverse reactions including mild and reversible diar-
rhea and skin rash. However, Yan et al341 reported that 
two cases of brain metastasis from non-small cell lung 
cancer,  developed  brain  hemorrhage  after  gefitinib 
therapy.
Available  antiproliferative  and  antiangiogenetic 
therapies show clear limitations below, we review the 
work of our laboratory during the past 20 years. It has 
led to the purification of a brain glycolipid, named 
neurostatin, that shows antiproliferative and antian-
giogenic activity two orders of magnitude better than 
temozolomide (Table 2). Experimental glioma treated 
with neurostatin became detectable to the immune 
system, allowing for its eradication.
Making Glioma Immunodetectable
Gangliosides, growth factor  
receptors and tumoral growth
Gangliosides are complex glycosphingolipid compo-
nents of the mammalian plasma membrane,   containing 
sialic acid. They were discovered by Ernst Klenk342 
and named on the basis of their isolation properties 
and high concentration in ganglion cells. Since 1956, 
when Svennerholm first showed the structural com-
plexity  of  gangliosides,343  his  nomenclature  based 
on the number of the sialic acid(s) and their chro-
matographic mobility has been commonly used. The 
structure  of  a  representative  ganglioside,  GM1,  is 
illustrated, along with similar representations of other 
gangliosides discussed in this review (Fig. 7). Since 
their discovery in the 1940s, gangliosides have been 
associated with a number of biological processes, such 
as growth, differentiation, and toxin uptake. Hypoth-
eses about regulation of these processes by ganglio-
sides are based on indirect observations and lack a 
clear definition of their mechanisms within the cell. 
The first insights were provided when a reduction in 
cell proliferation in the presence of gangliosides was 
attributed to inhibition of the epidermal growth factor 
receptor (EGFR). Since that initial finding most, if 
not all, growth factor receptors have been described 
as regulated by gangliosides.344 The effects of gangli-
osides on growth factor receptors may be understood 
based on three models: fibroblast growth factor recep-
tor (FGFR), platelet-derived growth factor receptor 
(PDGFR), and EGFR (Table 3). In the FGFR model, 
gangliosides  can  modulate  ligand  binding;  in  the 
second, PDGFR, gangliosides can regulate receptor 
Table  2.  Inhibitory  activity  (ID50,  mM)  of  O-acetylated 
(Compounds  2-5)  and  O-butyrylated  (compounds  6-9) 
compounds on U373MG human astrocytoma and C6 rat 
glioma cell lines.
compounda ID50 (µM) on  
U373 cells
ID50 (µM)  
on c6 cellsb
TMZc 401.20 ± 15.30 434.92 ± 18.65
GD1b .50 .50
O-AcGD1b 2.00 ± 0.45 0.23 ± 0.12
Bi-O-AcGD1b 2.54 ± 0.41 1.65 ± 0.35
Tri-O-AcGD1b 2.97 ± 0.52 3.56 ± 0.74
Tetra-O-Ac GD1b 2.93 ± 0.49 4.01 ± 0.56
O-ButGD1b 0.83 ± 0.34 0.32 ± 0.17
Bi-O-ButGD1b 1.50 ± 0.46 1.31 ± 0.39
Tri-O-ButGD1b 2.46 ± 0.52 1.74 ± 0.44
Tetra-O-ButGD1b 2.57 ± 0.59 1.88 ± 0.61
notes: aAll O-acetylated and O-butyrylated compounds were generated 
from ganglioside GD1b (compound 1); beGF was used as the mitogen 
for human U373MG or rat C6 cells. Data are expressed as mean ± SD 
of ID50 of four independent experiments performed in quadriplicate;   
cTemozolomide (TMZ) is the best glioma inhibitor clinically available.Glioma growth inhibition
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pit  internalization  and  ubiquitination,  but  ganglio-
sides may contribute to these functions and to sig-
nal  transduction  pathways.  Gangliosides  probably 
have a role in diverse biological structures that affect 
directly the duration of the signal and the localiza-
tion in the membrane of the growth factor receptor. 
For this purpose, the plasma membrane is organized 
into  microdomains  (lipid  rafts)  of  unique  ganglio-
side composition. Gangliosides were the first tumor-
  associated antigens described, and changes in cellular 
ganglioside composition were associated with altered 
growth  properties.345  In  other  experiments,  exog-
enous  administration  of  gangliosides  to  Neuro-2A 
neuroblastoma cells stimulated neurite sprouting and 
enhanced  axonal  elongation.346  Therefore,  ganglio-
sides are involved in controlling both, growth and 
differentiation, by modulating growth factor receptor 
activity.347 The original finding demonstrated that cell 
growth stimulated by fibroblast growth factor (FGF) 
was suppressed by exogenous addition of saturating 
amounts of gangliosides, that inhibited FGF receptor 
activity. The PDGFR348 and EGFR349 activities were 
also regulated by gangliosides, and the number of 
growth factor receptors found to be modulated by gan-
gliosides has been growing since 1990. References to 
studies of growth factor receptor activities regulated 
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Figure 7. General structure of a ganglioside. The structure of ganglioside GM1 is shown in detail. The Svenerholm shorthand is used: G, ganglioside;   
M, monosialo; D, disalo; and T, trisialo. The carbohydrate backbone consist of the following sugars: Gluc, glucose; Gal, galactose; GalNac, N-acetylgalac-
tosamine; and NANA, N-acetyl Neuraminic acid (sialic acid). The ceramide (Cer) is composed of sphingosine substituted in the amino group by long-chain 
fatty acid, typically stearic (C18), or C16, C20, or C22.
Table 3. effects of gangliosides on growth factor receptors.
Growth factor Ganglioside References
FGFR GM1 426, 426–430
GM2 431
GM3 422, 432, 433
GD1b 426
GT1b 426
PDGFR GM1 423, 434–440
GM2 434, 438–440
GM3 423, 434, 438, 442
GD1a 434, 438–440
GD3 434
GT1b 434, 438–440
eGFR GM1 424, 436, 437, 444–447
GM2 444, 445, 447
notes: effects of gangliosides on growth factor activity. Gangliosides 
have been associated with a number of biological processes, such as 
growth, differentiation, and toxin uptake. Regulation of these processes 
by  gangliosides  are  based  on  indirect  observations  and  lack  a  clear 
definition of their mechanisms within the cell.
dimerization; and finally, in the EGFR, gangliosides 
may affect receptor activation state and subcellular 
localization. These three models may be extended to all 
growth factor receptors, bearing in mind that the three 
models may not be mutually exclusive. Gangliosides 
may not act independently of well-  established mech-
anisms of receptor regulation, such as   clathrin-coated Nieto-Sampedro et al
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by gangliosides are provided in Table 3. Gangliosides 
can now be appreciated for their structural role in 
the organization of plasma membrane lipid microdo-
mains, as well as for their role in regulating growth 
factor receptor signaling processes.350
Natural and synthetic regulators  
of glial proliferation
The number of glial cells in the mammalian brain 
remains stationary throughout adulthood,351,352 thanks 
to the concomitant presence of specific mitogens and 
mitogen inhibitors.353 Definite evidence for the exis-
tence in brain of specific inhibitors of astroblast divi-
sion was presented by Nieto-Sampedro354 and soon 
confirmed.355 The inhibitor had epitopes in common 
with both, the carbohydrate moiety of the epidermal 
growth factor receptor (EGFR) and with human blood 
groups. Determination of its structure was facilitated 
by realizing its glycolipidic nature,356 which led to 
preparation of brain ganglioside extracts. The inhibi-
tor was purified to homogeneity, using a combination 
of conventional and high performance ion-exchange 
chromatographies. A combination of bidimensional 
nuclear  magnetic  resonance  (NMR),  MALDI-TOF 
mass spectrometry and biochemical studies,   permitted 
us to conclude that the inhibitor was O-acetylated 
GD1b.357 This very scarce ganglioside was called neu-
rostatin, attending to its source and biological activity. 
It inhibited the proliferation in culture of both primary 
astroblasts and glioma cells (both rodent and human) 
at nanomolar concentrations, both in defined medium 
or in the presence of 10% foetal calf serum. Synthetic 
oligosaccharide analogues of neurostatin inhibited the 
division of astroblast, glioma and neuroblastoma cells 
in culture358,359 and promoted the destruction in vivo 
of an experimental rat brain glioma.360 Compounds 
like  neurostatin  probably  arrest  glioma  growth  by 
direct antimitotic action on the tumoral cells, affect-
ing lipid raft microdomains and interfering with mul-
tiple signals regulating cell cycle progression (Fig. 4). 
Neurostatin-like compounds may also act indirectly, 
by activating CD4 and CD8 positive immune cells. 
Neurostatins may be the new type of chemotherapeu-
tic agent that will permit glioma eradication.
Glioma growth inhibition by a synthetic 
tetrasaccharide, TS4
The  synthetic  tetrasaccharide  α-D-GalNAc-(1-3)-
β-D-Gal-(1-4)-[α-L-Fuc-(1-3)]-β-D-GlcMe  (TS4), 
structurally related to blood groups, was an analogue 
of the carbohydrate moiety of neurostatin (Fig. 9). 
It was the best first generation synthetic inhibitor of 
astroblast and astrocytoma growth, designed based on 
its immunological properties before neurostatin struc-
ture was known.358,359 TS4 inhibited the proliferation 
of C6 rat glioma cells in culture, as well as the growth 
of brain tumors formed after intracerebral transplan-
tation of C6 cells.360 As expected from the cytostatic 
action of TS4 on glioma cells in culture, TS4-treated 
tumors were substantially smaller than controls. This 
action was probably mediated by two plasma mem-
branes C-lectin type proteins of apparent molecular 
weight 250 kDalton and a 150 kDalton (isolated by 
affinity chromatography on immobilized TS4 from 
both  C6  cells  and  brain  tissue;  Díaz-  Mauriño  and 
Nieto-Sampedro,  unpublished).  TS4-like  or  blood 
group-like  cell  surface  molecules,  together  with 
their binding proteins, define a cell adhesion system 
involved in the control of cell division. These cell 
adhesion systems interact with tyrosine kinase path-
ways at more than one level, mediating growth or its 
inhibition.361–363 Interaction of soluble TS4 with cell 
surface glycan binding proteins, mimicked cell-cell 
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Figure 8. Dose-response of the inhibition by TS4 of C6 glioma cell divi-
sion. Inhibition of glioma cell growth, promoted by 10% fetal calf serum, 
was measured as incorporation of tritiated thymidine into cultured cells 
and  correlated  with  the  proportion  (%)  of  viable  cells  determined  by 
counting cell number. The concentration of TS4 that inhibitedby 50% [3H] 
Thy incorporation (ID50) was 110 µM. At the maximal concentration of 
TS4 tested in vitro (4 mg/ml; 102% +	9% inhibition), 96% of the cells were 
viable (not shown).Glioma growth inhibition
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Figure 9. Structures of neurostatin (O-acetyl GD1b) and O- butanoyl-GD1b. O-acetyl-GD1b (neurostatin) is a natural, GD1b derived, inhibitor of astroblast 
and astrocytoma division. Its structure and scarcity limits its stability and availability. Therefore, we prepared O-acetylated and O-butyrylated GD1b by 
chemical synthesis.
contact, and evoked inhibition of cell proliferation 
and tumor growth.
TS4 binding to glioma cells made  
them immunovisible
Because  TS4  was  cytostatic  for  C6  cells  in  culture, 
finding that TS4-treated tumors were smaller than con-
trols was expected. However, in addition, the tumors 
appeared  necrotic.  Tumor  appearance  suggested  that 
the  tumors  had  grown  comparatively  large  and  later 
had been destroyed (Figs. 10 and 11). C6 glioma cells 
originated from Wistar rats and, when transplanted on 
isogenic  hosts,  proliferated  unhindered  and  migrated 
without causing vasculature disruption. The effects of 
TS4 treatment in vivo went beyond interference with 
cell division and caused transformed cell apoptosis and 
tumor destruction. Probably, TS4 binding activated indi-
rectly other tumour toxicity mechanism/s. At least four 
cell-mediated actions, not mutually exclusive, could lead 
to tumor destruction: (i) inhibition of tumor neovascu-
larization; (ii) activation of microglia; (iii) activation of 
natural killer (NK) cells and iv) activation of cytotoxic 
lymphocytes  (CTL).360  The  enhanced  immunogenic-
ity of TS4-treated glioma cells seemed related to their 
increased expression of connexin 43, observed in glioma 
cell cultures treated with the oligosaccharide.361,362
Although CD8 positive (CD8+) cells with lym-
phocyte  morphology  infiltrated  C6  tumors,  both 
TS4-treated as well as untreated, they did not pre-
vent the growth of untreated glioma controls. There-
fore, simple recruitment of extra lymphocytes, not 
observed after TS4 infusion into normal brain, was 
not involved in TS4-induced tumor destruction. Two 
types of infiltrating CD8+ cells were observed which, 
judging by their size and morphology, may be NK 
cells and CTLs (Fig. 10).360 Activation of NK cells 
requires activator binding to the NK receptor protein, 
NKR-P1 and TS4-like oligosaccharides are ligands of 
this protein.364,365 The oligosaccharide activators must 
be presented as lipid or pseudolipid micelles,364 but 
this manner of presentation could be mimicked by 
TS4 bound to its C lectin receptors on the surface of 
C6 cells. The specificity of NKR-P1 and of the TS4 
receptor lectins is such, that each binds preferently 
to sugar sequences at opposite ends of the TS4 mol-
ecule (Fig. 13). Hence, TS4 bound to lectin receptor 
on C6 membranes could still associate to NKR-P1, 
leading to NK cell activation and glioma destruction.
Intercellular junctions, connexin 43 
expression and glioma growth
Transfection of C6 cells with cDNA coding for the 
gap junction protein Cx43, caused decreased prolif-
eration of glioma cells.361,362 Transfected cells showed 
molecular disturbances in the IGF system,366 which 
made the tumor cells detectable by host CD8+ cyto-
toxic lymphocytes.367 The possibility that TS4 could 
enhance Cx43 expression by glioma cells, was tested 
by treating equal numbers of exponentially growing 
C6 cells with either, TS4 solution (final concentration 
1 mg/ml or 1.4 mM), or with the same volume of PBS. 
TS4-treated cells showed complete arrest of cell divi-
sion, but maintained viability. Controls, continued to 
grow normally. Northern blots of RNA from control Nieto-Sampedro et al
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Figure 10. CD-8 immunoreactive cells in and around a brain glioma. Saline-treated C6 glioma tumours, 21 days following transplantation of 105 cells into 
brain. (A–c) The tumors were infiltrated by CD8-positive cells of two types: (B), small, intensely staining, and (c), larger, less immunoreactive. (D), Tumors 
treated with TS4 were smaller than saline-treated controls and their appearance was necrotic. (e, F) CD8-positive cells in TS4-treated tumors were more 
numerous, stained more intensely, and were larger than similar cells in controls. High numbers of CD8-positive cells were observed infiltrating the tumor, 
forming a gradient of decreasing immunoreactivity towards adjacent tisue (star). The sections werecounter stained with cresyl violet. Magnification bars: 
A, D, 230 µm; B, C, e, F, 23 µm.
and TS4-treated cells, performed using a Cx43 cDNA 
probe, indicated a specific increase in expression of 
Cx43 mRNA in TS4-treated cells. The increase in 
Cx43 mRNA expression, ranged from 2.5 to 2.9-fold 
in four different experiments (average ±17%, n = 4). 
Cx43  expression  in  vivo,  in  tumors  treated  with 
TS4 solution (20 mg/ml) during 14 days, could not 
be observed by in situ hybridization with the same 
probe, as treated tumor cells were not viable.
New synthetic glioma inhibitors
The synthesis of the tetrasaccharide TS4 was rather 
long and labour-intensive. To overcome this limita-
tion, we designed a simpler synthesis of analogues Glioma growth inhibition
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Figure 11. Infiltration of glioma by microglia or macrophages (GIMs). OX-42 (CD 11b) immunoreactive cells infiltrating C6 glioma tumors, 21 days after 
transplantation of C6 cells (104 cells/2 µl) into the parietal cortex. The tumors were treated during the 14 days previous to sacrifice with: (A), saline solution; 
(D), TS4 solution in saline. Immunoreactivity was intense in and near the tumor, sharply decreasing with distance (D, star). (B) Immunoreactive cells in 
normal tissue had the morphology of ramified microglia. (c), In saline-treated tumors, infiltrating immunoreactive cells were round (arrowheads), whereas 
(e), most CD11b-positive cells in TS4-treated rats were slightly elongated (arrowheads) and, frequently, particularly in cells near blood capillaries, had 
short processes (F). Sections were counterstained with cresyl violet. Bars: A, D, 230 µm; B, e, 23 µm; F, 47 µm.
exhibiting the main structural features of TS4.368–371 
An octyl N-acetylglucosaminide derivative with a 
pentaerythritol chain at position 6 (Compound 1, 
Chart 1) inhibited the growth of a neuroectodermic 
tumor implanted in rats and, when loaded on a slow-
delivery polymer disk, caused the destruction of cul-
tured human astroblastoma, obtained after surgical 
biopsy.369 Compound 1 also inhibited the division 
of human U-373 glioma cells in culture, although 
with a modest ID50 value (43 mM). A variety of 
di- and monosaccharides were readily synthesized 
and evaluated as inhibitors of neural tumor growth. 
In order to get compounds with improved activ-
ity, a new series of monosaccharides was obtained Nieto-Sampedro et al
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Figure 12. Neurostatins inhibit experimental glioma growth in nude mice. (A) Growth of C6 glioma cells xenografted on nude mice. effects of GD1b, O-Ac 
GD1b and O-But GD1b. when tumors reached the required size (120 mm3; day 12), they were treated with PBS or with the gangliosides GD1b, O-Ac 
GD1b or O-But GD1b (8 mg/kg animal in PBS, in 5 injections from day 12 to 24). Tumor growth was evaluated determining the tumor volume every three 
days. (B) Representative images of tumor appearance at the end of the experiment (day 33). Treatment with PBS was the vehicle control and GD1b was 
used as inactive ganglioside control. 
notes: Daily growth statistical differences: *P , 0.05 vs. PBS; **P , 0.01 vs. PBS; +P , 0.05 vs. GD1b; ++P , 0.01 vs. GD1b. Overall growth 
statistical differences: #P , 0.05 vs. PBS; ##P , 0.01 vs. PBS; &P , 0.05 vs. GD1b; &&P , 0.01 vs. GD1b, calculated by ANOvA followed by post-
hoc Tukey test.
by    systematic    modification  of  the  substituents  at 
positions 1, 2, 3, and 6 of the glucosamine back-
bone, and tested as inhibitors of proliferation on 
rat (C6) and human (U-373) glioma.370 The results 
obtained indicated that the activity was increased by 
a long hydrocarbon chain at position C-1 of the glu-
cosamine backbone, the most inhibitory compound 
being  the  oleyl   glycoside  2  (Chart  1). To  obtain 
information about its mode of action, metabolite 
changes in C6 glioma cells were analyzed after treat-
ment with glycoside 2, using high-resolution magic 
angle  spinning  (HR-MAS)  1H  NMR.371  The  data 
obtained from the 1H NMR spectra of the different 
experiments suggest that glycoside 2 inhibited cell 
division (IC50 approx. 10 µM) by inhibiting de novo 
synthesis of fatty acids. At higher concentrations 
(above  40  µM),  a  significant  ratio  of  cell  death 
occurred through apoptosis.
Neurostatins, natural brain antimitotics
Neurostatin,  purified  from  rat  and  bovine  brain 
extracts,356,357 had epitopes in common with both, 
the carbohydrate moiety of the epidermal growth 
factor  receptor  (EGFR)  and  with  human  blood 
groups.354,355  This  very  low  abundance  modified 
ganglioside, like its synthetic oligosaccharide ana-
logues, inhibited in culture the division of astro-
cytes,  glioma  and  neuroblastoma  cells354,359  and Glioma growth inhibition
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Figure 13. Cell adhesion systems interact with tyrosine kinase pathways at more than one level, mediating growth or its inhibition. Interaction of soluble 
neurosttin or analogues with cell surface glycan binding proteins, mimick cell-cell contact, and evoke inhibition of cell proliferation and tumor growth.
promoted, in vivo, the immune destruction of an 
experimental  rat  brain  glioma.360  Determination 
of  the  precise  structure  of  neurostatin  required 
the  purification  of  comparatively  large  amounts 
of the molecule. The   fractionation of the amounts 
of brain tissue required was facilitated by prepa-
ration  of  ganglioside  extracts.371  Neurostatin  was 
purified  from  such  extracts,  using  a  combina-
tion  of    conventional  and  high  performance  ion-
exchange  and  reverse  phase  chromatographies.357   
O O
O
O
O
O
O
HO
HO
HO
HO
HO
OH OH
OH
CH3
NH
CH3
CH3(CH2)7
NH
12
chart 1. A long hydrocarbon chain at position C-1 of the glucosamine backbone of synthetic glycolipids increased their inhibitory activity.Nieto-Sampedro et al
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The purification to   homogeneity of neurostatin per-
mitted the determination of the inhibitor structure, 
combining  bidimensional  nuclear  magnetic  reso-
nance (NMR), MALDI-TOF mass spectrometry and 
biochemical studies. We concluded that neurostatin 
was GD1b, 9-O-acetylated on the outer sialic acid 
residue (Fig. 9). The acetylated ganglioside inhib-
ited  the  proliferation  in  culture  of  both  primary 
astroblasts and glioma cells (both rat and human) at 
nanomolar concentrations, either in defined medium 
or in the presence of 10% foetal calf serum.357
The O-acetylated forms of gangliosides GD3, GT3, 
GD1b, GT1b and GQ1b are present in neural tisue, 
at  developmentally  regulated  concentrations.372–374 
The expression of O-acetyl-GD3 and O-acetyl-GT3 
is particularly high during the O2A precursor prolif-
erative stage.374 GD3 is overexpressed in many types 
of tumors,375 whereas O-acetylated GD3 is present 
in  fast  growing  tumors,  such  as  melanoma.376  In 
contrast, pure neurostatin was cytostatic for astro-
cytes and glial-derived cell lines, several of them 
capable of malignant growth. Thymidine incorpora-
tion into rat C6 glioma cells or human astrocytomas 
U-373 and U-118, was inhibited in a concentration-
dependent manner, like for TS4 (Fig. 8), but with 
IC50 values ranging from 200 to 450 nM (Table 2). 
In contrast, primary rat fibroblasts or the fibroblast 
line 3T3, mouse neuroblastoma N2A or human neu-
roblastoma SH-SY5Y, were not affected, suggesting 
that the antimitotic activity of neurostatin addressed 
selectively cells of glial lineage. Neurostatin inhib-
ited glial proliferation, regardless of whether or not 
the cells required mitogens to enter division. Thus, 
it inhibited proliferation of human U-373 astrocy-
toma, a cell line probably autocrine and capable of 
dividing in serum-free or growth factor-free culture 
medium.
New semi-synthetic inhibitors
When  ganglioside  GD1b  was  O-acetylated  in  its 
outer  sialic  acid,  it  became  the  potent  inhibitor 
of  astroblast  and  astrocytoma  division,  we  called 
neurostatin.356,357 Because neurostatin showed speci-
ficity for cells of astroglial lineage, it was a suitable 
candidate for treatment of CNS astrocytomas.356,357 
However, the need to prepare and purify neurosta-
tin from brain extracts, limited the availability and 
purity of the compound.357,377 Moreover, the O-acetyl 
group of neurostatin was very labile to hydrolysis 
under physiological pH   conditions.357 These limita-
tions prevented the application of the compound to 
in-vivo studies and made its prospective clinical use 
virtually impossible. In order to overcome these lim-
itations, we proposed to use a semi-synthetic alterna-
tive to brain neurostatin, a method that permitted to 
obtain neurostatin in larger amounts.378 We hypothe-
sized that an O-acyl aliphatic chain longer than acetyl 
(ie, butyryl), may lead to neurostatin analogues more 
resistant  to  hydrolysis  that  neurostatin  itself,  also 
preventing the degradation of the natural compound 
by  specific  enzymes.  Gangliosides  O-Ac  GD1b 
(Neurostatin; Galβ1-3GalNAcβ1-4[9-O-Ac Neu5Ac 
2-8Neu5Ac  α  2-3]Galβ1-4Glcβ1-1′-ceramide) 
and  O-But  GD1b  (Galβ1-3GalNAcβ1-4[9-O-But 
Neu5Acα2-8Neu5Acα2-3]Galβ1-4Glcβ1-1′-
ceramide) were obtained by chemical O-acetylation 
or O-butyrylation of GD1b,378,379 using a modifica-
tion  for  gangliosides380  of  the  original  method  of 
Ogura et al.381 Ganglioside GD1b (125 µg) was dis-
solved in dimethylsulfoxide (DMSO; 12.5 µl) and 
treated with either trimethyl orthoacetate (TMOA; 
Sigma-Aldrich) or trimethyl orthobutyrate (TMOB; 
Sigma-Aldrich, St Louis, MO) in 500 molar excess, 
in the presence of p-toluensulfonic acid (0.0125 mg; 
Sigma-Aldrich) as catalyst. The reaction mixture was 
maintained for 8 hours in the darkness at 18–21 °C 
and acylation was stopped by addition of methanol 
(1 ml). The mixture was desalted by reverse phase 
filtration382 and O-substituted gangliosides were puri-
fied by preparative thin layer chromatography.383
Both,  O-Ac  GD1b  and  O-But  GD1b  (Fig.  9), 
had  similar  inhibitory  activities  on  rat  C6  glioma 
cells (ID50, 230 and 320 nM, respectively) and rat 
C6 glioma cells transfected with green fluorescent 
protein (C6-GFP). Inhibition of division of C6 cells 
promoted by EGF and analyzed by flow cytometry, 
showed that the inhibitors maintained a large pro-
portion (60%) of the glioma cells in the resting G0 
phase, compared to 47% in the absence of inhibitor 
(Fig. 12). Inhibition of glioma proliferation occurred 
without toxic or inhibitory effects for fibroblasts or 
neuroblasts,  at  the  maximal  concentration  tested 
(10 mM).378 Therefore, use in vivo was possible. The 
anti-tumoral  activity  in-vivo  of  compounds  O-Ac 
GD1b and O-But GD1b was tested on two glioma 
models: (i) a glioma xenografts in Foxn1nu/nu nude Glioma growth inhibition
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mice; (ii) intracranial glioma transplanted in rats (C6 
or C6-GFP).378
Female  Foxn1nu/nu  nude  mice  were  subcutane-
ously injected in the right flank with a suspension 
of 3 ×	106 C6 cells in serum-free DMEM medium. 
Treatment  with  inhibitors  was  started  when  pal-
pable tumors reached a volume of about 120 mm3. 
The animals were treated by intratumoral injection 
(8 µg/kg animal in PBS in 5 injections, from day 
12 to day 24) of O-Ac GD1b and O-But GD1b, and 
the tumor volume was compared to those of con-
trols injected either GD1b or PBS (vehicle). Tumor 
dimensions were measured every 3 days, and tumor 
volume was calculated as (width)2 × length × π/6. 
Tumor volume index was calculated using the differ-
ence between the measured volume and the volume 
measured at the start of the treatment. Additionally, 
the time-course of growth was adjusted to a straight 
line  to  compare  the  slopes  (tumor  growth  rate) 
after the various treatments (Fig. 12). The animals 
were sacrificed 33 days after tumor implantation 
and tumor progression evaluated. Two independent 
experiments were carried out (n = 8). Neither, the 
PBS solvent nor the parent ganglioside GD1b, had 
any inhibitory effect on tumor growth. On the other 
hand, one single intratumoral injection of low con-
centration  of  chemically  substituted  O-Ac  GD1b 
and O-But GD1b, inhibited tumor growth signifi-
cantly (Fig. 12A), when compared to the vehicle 
(PBS) and the parent compound, GD1b, from day 
27 after cell implantation until the end of the exper-
iment (day 33). O-But GD1b showed the highest 
inhibitory activity (Fig. 12A and B), reducing tumor 
growth by 49% at day 33 compared with the PBS 
control and 45% when compared with the unmodi-
fied ganglioside (GD1b). O-Ac GD1b also inhib-
ited the tumor growth, but it was less effective than 
O-But GD1b (Fig. 12A and B). The overall tumor 
growth rate was assessed comparing the slopes of 
the time-course of tumor growth: compared to con-
trols (PBS and GD1b), both O-acyl compounds sig-
nificatively reduced tumor growth rate.378
Mechanisms of Growth Inhibition
Direct inhibition of glioma proliferation
Growth  factor  signal  transduction  pathways, 
often  upregulated  in  brain  tumors,  may    contribute 
to    oncogenesis  through  autocrine  and  paracrine 
  mechanisms. The Ras signaling pathway is frequently 
overactive in gliomas. Receptor tyrosine kinase inhibi-
tors, antireceptor monoclonal antibodies and antisense 
oligonucleotides, are approaches under investigation 
to regulate aberrant growth factor signaling pathways 
in brain tumors.384 Inhibitors of tyrosine-kinase recep-
tors, that inhibit the Ras signaling pathway, also inhibit 
the growth of malignant gliomas. Cytokines PDGF 
and EGF play important roles in glial development 
and oncogenesis.155,385,386 The EGF receptor (EGFR) is 
mainly expressed in glioblastoma multiforme,155 while 
the receptor for PDGF (PDGFR) is expressed in most 
types of gliomas.385 PDGFR-A and PDGFR-B expres-
sion were observed in highly proliferating tumor cells, 
as well as in endothelial cells.385,387 Both growth fac-
tor signal transduction pathways are involved in can-
cer stem cell proliferation and glioma growth, but we 
do not know how neurostatin or TS4 interfere with 
them. The tetrasaccharide had receptors on the plasma 
membranes of neural cells. Two C-lectin type pro-
teins, of apparent molecular weight 250 kDalton and 
a 150 kDalton, respectively, were isolated by affinity 
chromatography  of  solubilized  plasma  membranes 
from either C6 cells or from brain tissue on immobi-
lized TS4.388 TS4-like molecules or membrane-bound 
neurostatin,  together  with  their  receptor  proteins, 
define a cell adhesion system that may be involved 
in cell division control (Fig. 13). Cell adhesion sys-
tems interact with tyrosine kinase pathways at more 
than one level, mediating signaling of growth or its 
inhibition.361–363,389 Interaction of soluble TS4 or neuro-
statin with cell surface glycan binding proteins, mim-
icked cell-cell contact, and evoked inhibition of cell 
proliferation. Such inhibition was also observed as a 
significant decrease in the respose to mitogen, ie, dim-
inution of the number of cells incorporating bromode-
oxyuridine (BrdU), or showing inhibited expression 
of phosphohistone H3 (pHH3), a mitosis marker that 
is phosphorylated in the late G2 phase of the cell divi-
sion cycle. Valle Argos et al390 observed that tumors 
treated with O-Ac GD1b or O-But GD1b incorporated 
48% or 65% less BrdU, and expressed three times less 
pHH3, than tumors treated with PBS. The transition 
of G1 to phase S is regulated by cyclin D1, kinase 
CDK6 and the cell cycle inhibitors p21 and p27. The 
expression of both cyclin D1 and CDK6 was reduced 
1.7 and 2.8 times, respectively, in tumors treated with Nieto-Sampedro et al
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neurostatin, and 3 and 3.4 times if the tratment was 
with O-But GD1b. On the other hand, the cell cycle 
inhibitor p27 was overexpressed after treatment with 
neurostatin (5-fold) or O-But GD1b (6.4-fold). Similar 
increases were observed for p21 inhibitor.390 Tumoral 
growth inhibition occurred with concomittant activa-
tion of pro-apoptotic proteases, such as caspase-3.
Indirect, immune cell-mediated  
glioma destruction
C6  glioma  cells  originate  from  Wistar  rats  and, 
when transplanted into isogenic hosts, proliferate 
unhindered and migrate without causing vasculature 
disruption. Because TS4 was cytostatic for C6 cells 
in culture, it was expected to find that TS4-treated 
tumors would be smaller than controls (Fig. 2C). 
However, in addition, the tumors appeared necrotic. 
Tumor appearance suggested that the tumors had 
grown comparatively large and, at a latter time, had 
been destroyed (Figs. 10 and 11). Destruction of 
tumors treated with neurostatin or TS4, suggested 
that the glycocompounds activated indirect toxicity 
mechanism/s. At least four cell-mediated actions, 
not mutually exclusive, may lead to tumor destruc-
tion: (i) activation of natural killer (NK) cells; (ii) 
activation  of  cytotoxic  lymphocytes  (CTL);  acti-
vation of microglia, and (iii) inhibition of tumor 
neovascularization.  Each  of  them  will  be  briefly 
considered.
CD8+  cells  with  lymphocyte  morphology  infil-
trated  all  C6  tumors,  both  TS4-treated  as  well  as 
untreated, but did not prevent the growth of controls. 
Tumor destruction induced by TS4 did not involve 
simple recruitment of extra lymphocytes, since it was 
not observed after TS4 infusion into normal brain. Two 
types of infiltrating CD8+ cells were observed which, 
judging by their size, may be NK cells and CTLs 
(Fig. 10). Activation of NK cells requires activator 
binding to NKR-P1, and TS4-like oligosaccharides 
are ligands of this protein.364,365 The oligosaccharide 
activators must be presented as lipid or pseudolipid 
micelles,364 but this manner of presentation could be 
mimicked by TS4 bound to its C lectin receptors on 
the surface of C6 cells. The specificities of NKR-P1 
and that of the TS4 receptor lectins are such, that each 
could bind preferently to sugar sequences at oppo-
site ends of the TS4 molecule. Hence, TS4 bound to 
  lectin receptor on C6 membranes could still associate 
to NKR-P1, leading to NK cell activation and glioma 
destruction.
Various  reports  suggest  that  TS4-induced  Cx43 
expression could mediate CTL activation. Stable C6 
transfectants overexpressing Cx43, showed inhibition 
of proliferation391,392 and decreased tumorigenicity,393 
probably  related  to  improved  immune  response.285 
The  link  between  Cx43  expression  and  increased 
tumor immunogenicity, appears to be the IGF-I auto-
crine system. C6 transfectants overexpressing Cx43, 
showed altered expression of IGF-I-binding proteins 
(IGFBP)366  and  transfection  of  C6  with  antisense 
IGF-I cDNA also led to loss of tumorigenicity.394,395 
Antisense  IGF-I  cDNA  transfected  cells  expressed 
reduced levels of growth factor, were not tumorigenic 
and, in addition, transplantation of transfectant cells 
caused the regression of tumors formed by wild type 
C6 cells. CD8+ cytotoxic lymphocytes that had previ-
ously ignored the tumor, were activated by transfec-
tant cells.394 It is conceivable that a similar chain of 
events could be triggered by TS4 infusion. Increased 
expression of Cx43 by TS4 treated C6 cells, would 
also  lead  to  enhanced  immunogenicity,  cytotoxic 
lymphocyte activation and tumor destruction.
It  has  been  reported  that  reactive  microglia  sur-
round experimental tumors formed by rat glioma cells, 
and that tumors are infiltrated by numerous microglia-
  derived macrophages.396 In agreement with these obser-
vations, we found numerous OX-42 (CD 11b) positive 
microglial cells both surrounding and infiltrating C6 
tumours (Fig. 11). It is well established that microglia 
are efficient antigen-presenting cells, and both Morioka 
et al391 and ourselves have shown, using different exper-
imental models, that these brain cells react strongly to 
tumoral growth. The number of reactive microglia/mac-
rophages infiltrating the tumour increased 5 to 10-fold 
in neurostatin-treated tumours.397
Finally, the cytostatic activity of TS4 and neuro-
statin was not limited to neural cells. Proliferation of 
other cell types such as endothelial cells or fibroblasts 
was  also  inhibited,  though  at  concentrations  much 
higher.398 Therefore, at the high TS4 concentrations 
used  in  vivo,  endothelial  cell  division,  and  hence 
tumor  vascularization,  might  have  been  inhibited. 
This would help to inhibit tumor growth and possibly 
lead to tumor necrosis.
The biological role of blood group carbohydrates 
has never been established, but the results reported in Glioma growth inhibition
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previous papers suggested that they may be involved 
in  controlling  abnormal  cell  proliferation.355,359 
  Neurostatin and TS4-like analogues, in which glu-
cose was replaced by N-acetyl-glucosamine, or where 
N-acetyl-galactosamine  was  replaced  by  N-acetyl-
neuraminic (as in sialyl Lewis X, SiLex), had simi-
lar  antimitotic  properties.399  Sialic  acid  containing 
glycoproteins are common markers of transformed 
cells400 and SiLex has been found in tumors401 and 
in the sera of cancer patients.402 It has been proposed 
that interaction of SiLex with the endothelial selectin 
ELAM-1 mediates extravasation of tumoral cells and, 
hence, metastasis.403–406 Both fucose and sialic acid 
are  absolute  requirements  for  ELAM-1  binding,406 
but the effect of substituting sialic acid for GalNAc 
has not been tested. Neurostatin, TS4 and analogues 
could be also antimetastatic, if used at concentrations 
capable of competing for binding to the natural ligand 
of the selectin.
Glioma immunotherapy
The possibility of harnessing the potency and speci-
ficity  of  the  immune  system  to  destroy  tumours, 
underlies the growing interest in cancer immunother-
apy of our and other groups.407–409 The compromised 
viability of glioma cells after binding neurostatin or 
analogues, like TS4, may engage the immune system, 
presumably  by  attracting  numerous  microglia-de-
rived macrophages or dendritic cells to glioma debris. 
Thus, glioma antigens would cease to be cryptic and 
its presentation to NK and T cells would follow, lead-
ing to glioma destruction.
Another approach has used dendritic cells (DCs) 
to present tumor-associated antigens (TAA) thereby, 
generating  tumor-specific  immunity.410–412  DCs  are 
extremely  potent  antigen-presenting  cells,  special-
ized in inducing activation and proliferation of CD8 
cytotoxic  T  lymphocytes  (CTL)  and  helper  CD4+ 
lymphocytes.413 This unique property has prompted 
their  application  in  therapeutic  cancer  vaccination. 
In the design and conduct of DC-based immunother-
apy trials, several important considerations influence 
induction of a successful protective response.414 First 
is the source of tumor antigen that can be loaded onto 
DC. In case of unknown tumor antigens, the source of 
antigen is, by necessity, a tumor cell lysate, apoptotic 
tumor cells, whole tumor–derived RNA, or tumor-
derived exosomes.415 Second, it is important the way 
in which DCs are activated, because immature DCs 
can tolerize the antitumoral response.416 Other impor-
tant variables are dose, frequency, timing, and route 
of administration.417–422 Taking into account all these 
variables, most studies have shown that injection of 
mature  tumor  antigen-treated  autologous  DCs  into 
tumor-bearing hosts, induced protective and therapeu-
tic antitumor immunity in experimental animals and, 
for some malignancies, in patients.422,423 Mice receiv-
ing dendritic cells treated with tumor lysate before 
tumor implantation, demonstrated protective antitu-
mor immunity with prolonged survival (3 months) 
and even resisted a second tumor challenge. Tumor 
protection was associated with strong tumor-specific 
cytotoxic T-lymphocyte responses. Adoptive transfer 
of splenocytes or purified CD8 T lymphocytes trans-
ferred tumor protection to unimmunized mice in vivo. 
When given after tumor implantation in a therapeutic 
setting,  pulsed  dendritic  cells  prevented  malignant 
mesothelioma growth. However, with higher tumor 
load and delayed administration after tumor implan-
tation,  dendritic  cells  were  not  effective.407  Nearly 
twenty  years  of  experimental  immunotherapy  for 
malignant  glioma  have  yielded  important  insights 
in the mechanisms governing glioma immunology. 
However, although still considered promising, it is 
clear that immunotherapy, on its own, does notrepre-
sent the magic bullet in glioma therapy.
Genetically engineered models of glioma
There is little debate on the importance of murine 
models for advancing our understanding of the com-
plex  biology  of  gliomas. Various  types  of  in  vivo 
model  systems  have  been  developed  and  utilized, 
including  traditional  orthotopic  xenotransplants 
with established human glioma cell lines and, more 
recently, with primary human glioma cells enriched 
for surface expression of CD133.2,424 There is great 
interest in the further development of the CD133 pri-
mary tumor model system as this appears to be supe-
rior in recapitulating the diffuse infiltrative nature of 
the primary human disease. Whether the CD133 pri-
mary tumor system will prove to be a more accurate 
biological model or be more predictive in drug test-
ing than xenotransplant models with established cell 
lines is an area of current investigation.
In recent years, important advances have been made 
in the construction of genetically engineered mouse Nieto-Sampedro et al
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(GEM) models, harboring glioma-relevant mutations 
or combinations of mutations. In several cases, such 
GEMs  predictably  develop  gliomas  with  many  of 
the features of the human disease.1,14,425,426 Given the 
experimentally tractable nature of the mouse, these 
glioma-prone  GEM  models  are  beginning  to  shed 
light on a number of key issues such as, for example, 
the glioma cells of origin,427 the ordering of mutations 
and whether such events underlie various glioma sub-
types428 and the cooperative and epistatic relationship 
of such mutations. The complex heterotypic interac-
tions between the evolving tumor cell and the host 
microenvironment, among other issues central to the 
problem of gliomagenesis, may also be approached 
with GEMs. With further refinement, there is now 
increasing evidence that these GEM model systems 
will  provide  an  additional  vantage  with  which  to 
test the timing, dosing, and combination of drugs in 
the pipeline and assist in the development of drug 
response biomarkers.124,429 These models are ideal for 
investigating the biological mechanisms underlying 
tumorigenesis and for the functional validation of can-
didate genes identified through large-scale genomic 
analysis of tumor specimens. The need for accurate 
models is perhaps most acute in preclinical testing, 
where experimental data often determine the fate of 
a  drug  in  development. Although  additional  study 
is needed, it is widely anticipated that refined GEM 
models of glioma should enable the identification of 
tumor maintenance genes and the testing of agents 
targeting such mission critical lesions, thereby identi-
fying key targets, the best agent, and the right patient 
population ie, genotype; Sharpless and Depinho.430 
Thus, GEM models may permit culling of ineffective 
drugs and improve the design of trials for those enter-
ing phase I/II clinical trials. In addition, the availabil-
ity of refined GEM models that evolve through stages 
may help define the tumor grade where an agent or 
combination of agents may be most effective.
Micro RNA and glioma growth
MicroRNAs  (miRNAs)  are  short  single  stranded 
RNA  molecules,  that  serve  as  master  regulators 
of  gene  expression  in  a  sequence-specific  fashion. 
miRNAs bind to 3’untranslated regions (UTRs) of 
mRNAs  and  affect  the  translation  and/or  stability 
of that mRNA, leading to a reduction in the levels of 
protein. Tumors analyzed by miRNA profiling have 
exhibited  significantly  distinct  miRNA  signatures 
compared to normal cells from the same tissue.431 The 
abnormal levels of miRNAs in tumors have impor-
tant pathogenetic consequences. Some miRNAs are 
over-expressed in tumors and act as oncogenes, pro-
moting tumor aggravation by down-regulating tumor 
suppressors.432  Thus,  the  miR-17-  miR-92  cluster 
in T-cell acute lymphoblastic leukemia, reduces the 
level of the transcription factor E2F1; miR-21 in lung 
cancer cells downregulates the tumor-inhibiting fac-
tor PTEN; and miR-125b is an important repressor 
of p53, inhibiting p53-induced apoptosis in human 
neuroblastoma cells.433 On the other hand, tumors lost 
miRNAs generally participate in oncogene overex-
pression. For example, the let-7 family represses Ras 
and Myc oncogenes in cancers,434 and the miR-15-
miR-16-1 cluster down-regulates Bcl-2 and induces 
apoptosis in a leukemic cell line model.435
miR-26b is one of the miRNAs involved in the 
response  to  hypoxia,  a  well  documented  tumor 
microenvironment factor. A recent study confirmed 
that the expression of miR-26b was changed in sev-
eral human cancer cell lines including glioma cells.436 
miRNA profile analyses revealed that miR-26b was 
one of the significantly decreased miRNAs in glioma 
cells compared to normal brain tissues.436 However, 
the role of miR-26b in glioma development has not 
been well documented and little is known about its 
target  genes.  Additionally,  the  effect  of  abnormal 
expression of miR-26b on tumor grade needs to be 
addressed.  Erythropoietin-producing  hepatocellular 
(EPH) receptors and their Ephrin ligands constitute 
the  largest  sub-family  of  receptor  tyrosine  kinases 
(RTKs),  which  are  involved  in  many  biological 
processes  and  play  important  roles  in  disease  and 
  development.437 To date, fourteen Eph receptors have 
been found in mammals. They were divided into two 
distinct classes, A and B, based on the sequence homol-
ogy  of  their  extracellular  domains.  More  recently, 
EphA  receptors  and  their  corresponding  ligands 
have been implicated in numerous   malignancies.438 
Among  them,  EphA2  and  ephrinA1  are  the  most 
widely  studied  with  respect  to  development,  tum-
origenesis,  angiogenesis,  and  metastasis,  and  they 
may represent potential therapeutic targets because 
of their diverse functions in several types of cancer. 
Activation of the EphA2 receptor tyrosine kinase by 
ephrinA1  ligands  plays  important  roles  in  cellular Glioma growth inhibition
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signal   transduction.439 EphA2 is functionally altered 
in a number of cancers and has potential roles in the 
regulation of cancer cell growth, survival, migration, 
invasion,  and  angiogenesis.440–442  Increased  expres-
sion of EphA2 has been demonstrated in most   cancers 
of  epithelial  origin,  like  breast,443  ovarian,441,444,445 
prostate,445 melanoma,446 esophageal,447–449 lung car-
cinomas450  and  brain.451,452  Immunohistochemical 
analysis has revealed that EphA2 was strongly over-
expressed in 90% of GBM patient tumors,451 85% 
of  prostate  adenocarcinomas  and  76%  of  ovarian 
  cancers.442   Furthermore, the frequent over-expression 
of  EphA2  in  human  cancers  correlates  with  poor 
prognosis  and  increases  metastatic  potential.442  In 
epithelial cells, ectopic expression of EphA2 has been 
shown to result in a malignant phenotype in both in 
vitro and in vivo experiments.443 EphA2 has been pro-
posed as an attractive target for developing novel anti-
cancer therapeutic agents. Wu et al453 studied, using 
real-time PCR analysis, the expression of miR-26b in 
glioma cells and the tissues from glioma patients of 
defined grades. Proliferation, migration, and invasion 
were analyzed to confirm the effects of miR-26b in 
glioma cells. The regulation by miR-26b of EphA2 
was confirmed by the experiments of luciferase anal-
ysis,  Western  blotting,  and  Vasculogenic  mimicry 
(VM)  network  formation. They  found  that  ectopic 
expression of miR-26b in U251 and C6 glioma cells 
resulted  in  diminished  proliferation,  migration  and 
invasion activity, accompanied by a low level expres-
sion of EhpA2. VM formation was also abolished in 
glioma  cells  transfected  with  the  miR-26b  duplex. 
This study provides evidence that miR-26b acts as 
an antioncogene in glioma cells and is an important 
negative regulator of the EphA2 gene.
Future directions
The  progress  and  depth  of  understanding  of  the 
biology and genetics of glioma, together with truly 
manipulable  experimental  models,  now  offer  real 
opportunities for the development of effective thera-
pies. Despite significant gaps in our understanding, 
a wealth of information now exists about the clini-
cal and biological behavior of the tumors, the genetic 
pathways involved in gliomagenesis, the nature of the 
disease and how its heterogeneity contributes to its 
untractability. The therapeutic resistance is a hallmark 
of their malignancy, which raises the question of which 
genetic alterations should be targeted as drivers of 
tumor maintenance, which could be ignored because 
they are initially needed for tumor establishment, and 
which drive the glioma stem cell niche, thus provid-
ing a reservoir from which therapeutically resistant 
cells can emerge. To fully understand the relevance 
of this niche in driving therapeutic resistance, many 
critical questions remain to be answered, including 
whether CD133+ cells are equivalent to the actively 
proliferating tumor cells seen in routine histological 
analysis, or whether they represent a quiescent popu-
lation activated by ex vivo manipulations. It is also 
not yet clear whether there is a prognostic correlation 
between CD133+ and patient outcome, and whether 
CD133+ cells are selectively spared by radiation and 
chemotherapeutic drugs.
Our ability to isolate and culture neural and CSCs, 
astrocytes and oligodendrocytes and the creation of 
faithful models of this disease, coupled to enormous 
advances in genomic characterization of gliomas and 
functional  validation  of  causative  mutations,  offer 
the very real prospect of rapid and thorough preclini-
cal testing of compounds and other agents to directly 
answer the relevant questions. By identifying the weak-
nesses of the tumor, useful treatments for patients with 
these devastating diseases will become a reality. Thus, 
Chirasani et al431,454 reported very recently that endog-
enous neural precursor cells perform an anti-tumour 
response  by  specifically  targeting  stem-like  brain 
tumour cells. Neurospheres of neural precursor cells 
constitutively  release  in  vitro,  bone  morphogenetic 
protein-7 (BMP-7) and induce canonical bone mor-
phogenetic protein signalling in stem-like glioblastoma 
cells. Exposure of human and murine stem-like brain 
tumour cells to neurosphere-derived BMP-7 induces 
tumour stem cell differentiation, attenuates stem-like 
marker expression and reduces self-renewal and the 
ability for tumour   initiation. Neurosphere derived or 
recombinant BMP-7 reduces glioblastoma expansion 
from stem-like cells by down-regulating the transcrip-
tion factor Olig2. In vivo, large numbers of BMP-7-
expressing neural precursors encircle brain tumours 
in young mice, induce canonical BMP signalling in 
stem-like glioblastoma cells and can thereby attenu-
ate tumour formation. This anti-tumour response is 
strongly reduced in older mice. The results of Ketten-
mann and Glass groups431,454 indicate that endogenous 
neural   precursor cells protect the young brain from Nieto-Sampedro et al
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glioblastoma  by  releasing  BMP-7,  which  acts  as  a 
paracrine tumour suppressor, repressing proliferation, 
self-renewal and tumour-initiation of stem-like glio-
blastoma cells.
The main goal of any drug approach has to be 
induction of apoptosis of tumor cells given the hyper-
mutability of GBM as a response to the therapeutic 
challenge.  Antiangiogenic,  antiproliferative,  and 
antiinvasive strategies represent adjuvant strategies. 
Although  treatment  of  glioma  may  be  improved 
by  combining  chemotherapy  with  anti-angiogenic 
drugs,258 inhibiting angiogenesis in GBM may antago-
nise the efficacy of chemotherapeutic drugs by normal-
ising the function of the blood-brain barrier. Although 
it is unlikely that a single magic bullet will cure GBM 
and it is likely that multiple drug approaches may be 
needed, neurostatin and its analogues look like the 
experimental compounds closest to the magic bullet: 
a single compound inhibits division of both tumoral 
and endothelial cells, while making the tumor immu-
novisible and engaging the immune system to fight 
it. The development of enzymatic methods for the 
synthesis  of  neurostatin  and  related  compunds  in 
high yield,432,455 will make possible continuous intra-
tumoral injection of high concentrations of a chemo-
therapeutic  agent  capable  of  inducing  multimodal 
glioma destruction. Together with new advances in 
surgical treatment and radiotherapy,433,456 neurostatin 
chemotherapy will significantly prolong life of a rea-
sonably quality.
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